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B Summary 
 
Limb-girdle congenital myasthenic syndrome (LG-CMS) is a rare inherited neuromuscular disorder 
in humans. One major objective of the present study was the molecular genetic characterization 
of LG-CMS patients with tubular aggregates (TAs) in muscle biopsies. Mutations in glucosamine-
fructose-6-phosphate aminotransferase 1 (GFPT1) were identified as underlying molecular defect 
by a genome-wide linkage analysis and DNA sequencing of positional candidate genes.  The 
bifunctional enzyme GFPT1 catalyses the first and rate limiting step of the hexosamine 
biosynthetic pathway (HBP) leading to the formation of UDP-N-acetylglucosamine (UDP-GlcNAc) 
which is essential for posttranslational modification of serine and threonine residues of nuclear 
and cytoplasmic proteins. Although glutaminase and isomerase activities have been attributed to 
GFPT1, little is known about the regulation and subcellular localization of GFPT1. A defect in 
glycosylation is a novel underlying pathomechanism in a synaptic transmission disorder and the 
role of GFPT1 in CMS pathogenesis has not been defined yet.  
Immunoblot analysis revealed reduced GFPT1 protein levels in LG-CMS patients’ myoblast 
lysates. Furthermore, decreased levels of O-linked N-acetylglucosamine (O-GlcNAc) on proteins 
were observed in patients’ myoblasts and in mouse myoblasts (C2C12 cells) treated with Gfpt1 
siRNA.  
The analysis of the effects of LG-CMS associated GFPT1 mutations on enzymatic activity 
demonstrated that selected GFPT1 missense mutations have only small effects on the enzyme 
activity of the GFPT1 protein. Furthermore, the subcellular localization of mutant GFPT1 species, 
transiently expressed in SW13 cells, is almost consistent with that of wild-type GFPT1. Therefore, 
a deficiency of GFPT1 protein due to decreased synthesis or stability of the GFPT1 mutants 
seems to result in reduced levels of O-linked N-acetylglucosamine on proteins in LG-CMS patients’ 
myoblasts and might be the major factor at least in the pathogenesis of some GFPT1 associated 
LG-CMS.  
A second major objective was to elucidate the pathogenic mechanisms of a particular mutation in 
the 3’- untranslated region (UTR) of GFPT1 (c.*22C>A) observed in four independent families 
from Spain and Germany. Because this variant does not alter the GFPT1 open reading frame, its 
pathogenic relevance has not yet been established. The GFPT1 protein levels were reduced in 
patients’ myoblast samples carrying c.*22C>A heterozygously compared to controls, similarly as 
it had been observed in patients carrying other disease causing mutations of GFPT1. In a 
controlled assay, the association of GFPT1 c.*22C>A with reduced GFPT1 protein levels was 
confirmed. Furthermore, my data demonstrate that the c.*22C>A mutation in the GFPT1 gene 
allows for illegitimate binding of miR-206* and miR-600 resulting in reduced GFPT1 protein 
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expression. I found that reduced GFPT1 protein levels resulted from repression of translation 
rather than degradation of the mRNA. While it has been demonstrated before that miR-206 is 
expressed in muscle and involved in myogenesis, I first confirmed that the miR-206* (star-
strand) is expressed in skeletal muscle. The overlapping expression profiles of hsa-miR-206*, 
hsa-miR-600 and GFPT1 support the assumption that the binding of these miRNAs to the 3’-UTR 
of mutant GFPT1 mRNA might be pathogenetically relevant. Therefore, my results support a 
model in which the point mutation c.*22C>A in the GFPT1 3’-UTR creates a target site for miR-
206* and miR-600, which influences GFPT1 expression. Notably, the miR-206* is considerably 
upregulated in GFPT1 patients’ muscle compared to control muscle. 
In contrast to most other CMS causing genes which encode post-, pre- or synaptic proteins at the 
neuromuscular junction (NMJ), GFPT1 is ubiquitously expressed. Consequently, one challenge of 
the present thesis was to understand how reduction in GFPT1 protein levels results in selective 
vulnerability at the NMJ. The skeletal muscle-specific expression of miR-206* could explain the 
muscle-specific phenotype of CMS patients with the GFPT1 3’-UTR mutation.  
For the diagnosis, counseling and therapy of a patient, a precise molecular classification of CMS 
is of paramount importance. The identification of GFPT1 mutations in LG-CMS patients allows, in 
contrast to most other inherited disorders, an effective therapy since CMS patients with GFPT1 
mutations response well to acetylchoninesterase inhibitor treatment.  
My results suggest that formation of miRNA binding sites by mutations might be a relevant 
pathogenic factor in CMS and most likely in other Mendelian disorders as well. In keeping with 
this consideration, variants in the 3’-UTRs should be carefully evaluated during routine genetic 
diagnostic procedures.  
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C Zusammenfassung 
 
Die kongenitalen myasthenen Syndrome (CMS) bilden eine klinisch und genetisch heterogene 
Gruppe von neuromuskulären Erkrankungen, denen eine Signalübertragungsstörung der 
motorischen Endplatte zugrunde liegt. Im Fokus dieser Arbeit stand die seit längerem bekannte, 
distinkte Unterform der autosomal-rezessiv vererbten CMS mit Gliedergürtelbetonung (LG-CMS) 
und tubulären Aggregaten in der Muskelbiopsie. Durch genomweite Kopplungsanalyse und die 
anschließende Sequenzanalyse positionaler Kandidatengene gelang es, Mutationen im GFPT1-
Gen, das für das bifunktionelle Enzym glutamine—fructose-6-phosphate transaminase 1 (GFPT1) 
kodiert, als Ursache der LG-CMS zu identifizieren. GFPT1 ist das Schlüsselenzym des Hexosamin-
Stoffwechselweges (HBP) und essentiell für die posttranslationale Modifikation von Serin- und 
Threonin-Resten von nukleären und cytoplasmatischen Proteinen mit O-glykosidisch gebundenem 
N-Acetylglucosamin (O-GlcNAc). Der Zusammenhang zwischen CMS und einem 
Glykosylierungsdefekt ist ein neuer Pathomechanismus für neuromuskuläre 
Signalübertragunsstörungen, so dass diese Arbeit das Ziel  verfolgte, die molekularen und 
zellulären Auswirkungen der GFPT1-Mutationen zu charakterisieren, um die Rolle von GFPT1 in 
der CMS-Pathogenese zu verstehen.  
Es konnte gezeigt werden, dass die GFPT1-Proteinmengen in Myoblasten von Patienten mit 
GFPT1-Mutationen deutlich vermindert sind. Außerdem finden sich in Myoblasten von Patienten 
und in Mausmyoblasten (C2C12-Zellen), in denen die Gfpt1-Expression mit siRNA unterdrückt 
wird, verminderte Level von O-GlcNAc modifizierten Proteinen. Dahingegen konnte durch 
transient exprimiertes GFPT1 in HEK293 Zellen und nachfolgendem GDH Aktivitätstest 
nachgewiesen werden, dass GFPT1-Missensmutationen nur geringe Auswirkungen auf die 
Enzymaktivität haben. Zudem stimmt die subzelluläre Lokalisation von mutiertem GFPT1 mit der 
des Wildtyp Proteins weitgehend überein, so dass es vermutlich aufgrund verminderter Synthese 
oder Stabilität der GFPT1-Mutanten zum Verlust der Proteinfunktion kommt, die sich in 
reduzierten Levels von O-GlcNAc modifizierten Proteinen zeigt. 
Ein weiterer Schwerpunkt der vorliegenden Arbeit war die Analyse der c.*22C>A Mutation in der 
3‘-untranslatierten Region (UTR) von GFPT1, die in vier unabhängigen LG-CMS Familien aus 
Spanien und Deutschland identifiziert wurde. Auch bei diesen Patienten waren in Muskelbiopsien 
und kultivierten Myoblsaten deutlich verminderte GFPT1-Proteinmengen nachweisbar. Es konnte 
gezeigt werden, dass durch die Mutation in der 3‘-UTR von GFPT1 eine Bindestelle der miRNAs 
miR-600 und miR-206* entsteht. In Experimenten mit Reporterkonstrukten konnte bestätigt 
werden, dass durch die Bindung der miRNAs an die Zielsequenz die Expression von GFPT1 
tatsächlich vermindert wird. Dabei ergeben sich die verringerten GFPT1-Proteinmengen in 
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Myoblasten und Muskel von Patienten mit der Mutation c.*22C>A eher aus der Repression der 
Translation als dem Abbau der mRNA. Während bereits bekannt war, dass der sog. „Leitstrang“ 
der miR-206 im Muskel exprimiert wird und als muskelspezifische miRNA eine Rolle bei der 
Myogenese spielt, zeigt diese Arbeit, dass auch die miR-206* (star), der sog. „Folgestrang“ in 
humanem Muskel, Myoblasten, Myotuben und C2C12-Zellen vorliegt. Im Unterschied zu den 
meisten anderen CMS-Genen, die Komponenten der neuromuskulären Endplatte kodieren, wird 
GFPT1 ubiquitär exprimiert. Da durch die GFPT1 3‘-UTR-Mutation eine Zielsequenz für die 
muskelspezifische miRNA miR-206* entsteht, ergibt sich hierfür zumindest für Patienten mit 
dieser Mutation ein plausibler Erklärungsansatz. Mit der Identifizierung von Mutationen im GFPT1-
Gen konnten in der vorliegenden Arbeit Glykosylierungsdefekte als gänzlich neuer 
Pathomechanismus für kongenitale myasthene Syndrome beschrieben werden. Für die 
betroffenen Patienten bedeutet der Nachweis einer GFPT1-Mutation nicht nur die Möglichkeit 
einer gezielten genetischen Beratung, sondern erlaubt – im Gegensatz zu den meisten anderen 
erblichen Erkrankungen – auch eine wirksame Therapie, da bei Patienten mit GFPT1-Mutationen 
Acetylcholinesterasehemmer gut wirksam sind. Untersuchungen zu einer Mutation außerhalb des 
kodierenden Leserahmens des GFPT1-Gens weisen darauf hin, dass die Entstehung einer miRNA 
Bindestelle durch Mutationen im 3‘-UTR eine Ursache monogenetischer Erkrankungen darstellen 
kann und die Analyse der 3‘-UTR in der genetischen Diagnostik berücksichtigt werden muss.      
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D Introduction  
 
1 Neuromuscular junction (NMJ) 
 
The NMJ is a specialized synapse to communicate the electrical impulse from the motor neuron to 
the skeletal muscle in order to signal contraction. The synapse consists of the following three 
major structural elements [1, 2]: the presynaptic region containing the nerve terminal, the 
synaptic cleft and the postsynaptic surface of the muscle cell. It is designed to transmit the 
impulses from the nerve terminal to the muscle via the chemical transmitter acetylcholine (ACh). 
This neurotransmitter is synthesized in the motor nerve terminal by the enzyme choline 
acetyltransferase (ChAT) and packed into synaptic vesicles. Following the arrival of an action 
potential and the subsequent influx of presynaptic calcium by voltage-gated calcium channels 
(VGCC), the vesicles are released. They fuse with the plasma membrane of the nerve terminus 
and release the neurotransmitter acetylcholine (ACh) into the synaptic cleft. The neurotransmitter 
binds to the acetylcholine receptor (AChR) at the postsynaptic surface at a ratio of two ACh 
molecules per receptor. Ligand binding leads to the opening of the AChR ion channel, positively 
charged sodium ions enter through the central pore of the receptor and results in the 
depolarization of the postsynaptic membrane. The depolarization of the membrane potential 
leads to the activation of voltage-gated sodium channels (sodium channel isoform Nav1.4, the 
muscle sodium channel which is predominantly expressed in skeletal muscle [3, 4]) on the 
postsynaptic side. An action potential is generated and propagated, eventually leading to 
contraction of the muscle. ACh is hydrolyzed by the enzyme acetylcholinesterase (AChE) in the 
synaptic cleft of the NMJ. Its breakdown product, choline, can be re-synthesized into ACh in the 
motor neuron. The membrane potential of the presynaptic membrane is restored when voltage-
gated potassium channels open.  
During development, the formation of the postsynaptic apparatus is induced by agrin, which is 
released from the nerve terminal [5]. Binding of agrin to the low-density lipoprotein receptor-
related protein 4 (Lrp4) activates the muscle specific tyrosine kinase (MuSK) [6-8] which in turn 
is able to bind downstream of kinase 7 (Dok7) [9]. Activated MuSK also leads to the tyrosine 
phosphorylation of the AChR β-subunit [10]. It was shown that phosphorylation of this motif 
fosters binding of the membrane protein rapsyn to each AChR [11]. Rapsyn also interacts with 
the f-actin cytoskeleton, thus attaching the receptor to the cytoskeleton and being essential for 
AChR clustering [12].       
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Figure 1: Schematic representation of the neuromuscular junction (NMJ). 
The scheme presents the molecular signaling at the neuromuscular junction and the involved molecules in signal 
transmission and development of the apparatus [13]. See text for abbreviations and explanations.    
 
2 Congenital myasthenic syndromes (CMS) 
 
Impaired neuromuscular transmission causes some different neurological conditions, varying from 
poisoning with botulinum and snake venom toxins through the autoimmune mediated disorders 
such as the Lambert-Eaton myasthenic syndrome and myasthenia gravis to the hereditary 
congenital myasthenic syndromes (CMS) [14, 15]. Diseases of the NMJ affect presynaptic, 
synaptic or postsynaptic components and cause skeletal muscle fatigue. Congenital myasthenic 
syndromes are inherited human disorders characterized by defects in neuromuscular transmission 
[16, 17]. These rare hereditary neuromuscular disorders are caused by mutations in a number of 
different genes. There are no current information on the prevalence of CMS in Germany, but a 
recent study in the United Kingdom (UK) revealed that the UK detected prevalence of genetically 
confirmed CMS was about 9.2 cases per million children under 18 years of age [18]. To date, 14 
genes are known to cause CMS and as the majority of them are coding for NMJ proteins, the 
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disorder is classified according to the location of the mutant protein at the NMJ into presynaptic, 
synaptic and postsynaptic CMS [19, 20].    
 
2.1 Main clinical symptoms 
 
In general, the onset of the disease is shortly after birth or during early childhood. Some sporadic 
or late-onset CMS have been described as well [19, 20]. The main clinical features of CMS include 
abnormal fatigue and fluctuating muscle weakness. The disorder may be very severe, resulting in 
progressive muscle weakness, respiratory insufficiency, loss of ambulation and death [21]. The 
symptoms of CMS are sometimes similar to those of two other NMJ disorders, myasthenia gravis 
and Lambert-Eaton myasthenic syndrome. However, these disorders occur when the immune 
system attacks parts of the NMJ [22]. In contrast to autoimmune disorders, tests for AChR and 
MuSK antibodies are negative in CMS patients.  
 
2.2 Classification of CMS  
2.2.1 Presynaptic CMS 
2.2.1.1 CHAT mutations 
Presynaptic CMS is rare and only mutations in the protein choline acetyltransferse (ChAT), 
encoded by the CHAT gene, have been identified so far. The ChAT protein catalyses the 
production of ACh at the nerve terminals. Experiments in knockout mice have shown that ChAT 
affects synaptogenesis and coordinates synaptic maturation [23]. The CHAT mutations in CMS 
patients alter the stability, expression or kinetics of the ChAT protein. The onset of these CMS is 
at birth or in the neonatal period. Patients harboring mutations in ChAT show sudden episodic 
crises with apnea and they respond well to anti-AChE therapy [24-26].    
 
2.2.2 Synaptic CMS 
2.2.2.1 COLQ mutations 
Acetylcholinesterase (AChE) hydrolyses acetylcholine in the synaptic cleft of the NMJ. This 
asymmetric enzyme consists of one, two or three homotetramers of catalytic subunits (AChET) 
attached to a triple-stranded collagenic tail (ColQ) that anchors it in the synaptic basal lamina 
[27]. ColQ comprises an N-terminal proline-rich region attachment region (PRAD), a collagenic 
central domain and a C-terminal region enriched in charged residues and cysteines. Each ColQ 
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strand binds to the proline-rich region of an AChET tetramer [28]. In order to anchor the enzyme 
in the postsynaptic membrane, two binding domains in the collagen domain and residues in the 
C-terminal domain interact with perlecan and the extracellular domain of muscle-specific kinase 
(MuSK). Pathogenic mutations causing synaptic CMS have been identified in each ColQ domain. 
The resulting endplate AChE deficiency can be caused by mutations preventing the attachment of 
AChET to ColQ, producing a short single-stranded and insertion-incompetent ColQ or by impairing 
the triple-helical assembly of the collagenic domain and/or hindering insertion into the basal 
lamina [16]. These different consequences depend on the localization of the COLQ mutations. 
The first symptoms usually arise neonatally or during infancy and they are severe with significant 
lethal risk or less severe, respectively. ColQ patients do not benefit from anti-AChE therapy but 
they can be treated by ephedrine [29] or albuterol [30]. 
 
2.2.2.2 LAMB2 mutations 
In the literature, one case has been reported presenting with symptoms and signs of CMS 
associated with congenital nephrosis and ocular malformations. The molecular genetic analysis of 
this patient confirmed compound heterozygous mutations in the LAMB2 gene, encoding the beta2 
subunit of laminins. The patient did not benefit from cholinesterase inhibitors but the therapy 
with ephedrine was beneficial [31]. Laminins are glycoproteins of the basal lamina located at the 
NMJ and they seem to play an important role in synaptogenesis [32].      
 
2.2.3 Postsynaptic CMS 
2.2.3.1 AChR subunit mutations 
The most common type of CMS is postsynaptic CMS. Most cases are caused by mutations in 
AChR subunit genes. The adult muscle AChR is a pentamer comprising two α subunits, one β, 
one δ and one ε subunit. There is also a fetal form in which a γ subunit is expressed instead of 
the ε subunit. The five homologous subunits consist of a large N-terminal extracellular domain 
followed by three transmembrane domains (M1–3), an intracellular cytoplasmic domain, a final 
transmembrane domain (M4) and an extracellular C-terminus [33]. Each receptor has two ACh 
binding pockets, one at the α/ε interface and one at the α/δ interface.    
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Figure 2: Schematic representation of the acetylcholine receptor (AChR).  
(a) AChR is a pentameric membrane protein. (b) Each subunit consist of a large N-terminal extracellular domain 
followed by three transmembrane domains (1–3), an intracellular cytoplasmic domain, a final transmembrane 
domain (4) and an extracellular C-terminus. (c) The fetal form expresses the γ subunit instead of the ε subunit. 
(d) The adult muscle AChR comprising two α subunits, one β, one δ and one ε subunit. The figure was adapted 
and modified from [34].  
 
AChR mutations can be classified into two major classes: kinetic mutations with or without subtle 
AChR deficiency and mutations leading to major deficiency of AChR at the endplate by altering its 
expression. Kinetic mutations are subdivided into two types depending on their kinetic effect: 
‘slow-channel’ and ‘fast-channel’ mutations. Prolonged opening of the AChR channel and the 
following slow decay of the synaptic current are caused by slow-channel mutations. 
Physiologically, the fast-channel syndrome is the opposite of the slow-channel syndrome. Slow-
channel syndromes are caused by autosomal-dominant gain-of-function mutations, while all other 
CMS types are caused by autosomal-recessive loss-of-function mutations [16, 35-37]. 
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2.2.3.2 RAPSN mutations 
Mutations in the gene encoding rapsyn (receptor-associated protein of the synapse) are also 
classified as postsynaptic CMS. The rapsyn protein comprises several functional domains: a 
myristoylated N-terminal, 7 tetratricopeptide repeats (TPR) important for self-aggregation and 
binding to the muscle kinase MuSK, the coiled coil domain and the C-terminal domain that binds 
to β dystroglycan. Together with agrin, LRP4 (low-density lipoprotein receptor-related protein 4), 
MuSK and Dok-7 (downstream of tyrosine kinase 7) rapsyn clusters the muscle nicotinic ACh 
receptor at the postsynaptic membrane and connects it to the subsynaptic cytoskeleton through 
dystroglycan [7, 9, 38, 39]. The majority of the identified RAPSN mutations are located in the 
tetratricopeptide repeat domain of the rapsyn protein. Expression studies of cells co-expressing 
mutant rapsyn and AChR subunits revealed impaired recruitment of the receptor to rapsyn 
clusters [40]. Mutations in the RAPSN gene are a relatively common cause of CMS and most 
RAPSN CMS patients harbour the p.Asn88Lys mutation in exon 2 either homozygously or 
heterozygously [41, 42]. Both early and late onset phenotypes have been described and the 
clinical picture varies from severe to mild. Ptosis is seen in most patients with RAPSN mutations. 
Other frequent symptoms include respiratory crises and high arched palate. The patients respond 
well to AChE inhibitor therapy.  
 
2.2.3.3 MUSK and AGRN mutations 
Defects in MuSK and agrin are also known to cause CMS. There are two publications on 
mutations in agrin [43, 44] and three on mutations in MuSK [45-47]. The clinical phenotype and 
the disease severity of patients with MUSK mutations is very variable. Only the presence of ocular 
symptoms and fatigable limb weakness are common. The two CMS patients with AGRN mutations 
described so far presented with a fairly mild phenotype without bulbar and respiratory difficulties. 
MUSK as well as AGRN patients benefit from ephedrine treatment while the therapy with 
cholinesterase inhibitors is ineffective.   
      
2.2.3.4 DOK7 mutations 
First described in 2006, mutations in the DOK7 gene have been established as a common cause 
of CMS. The mutations in DOK7 are supposed to result in abnormal activation of MuSK signalling 
which leads to unstable NMJ with simplified pre- and post-synaptic structures [48-50]. 
Furthermore, experiments in zebrafish suggested that Dok-7 deficiency also impairs slow muscle 
fibre organisation independent of Musk [51]. First symptoms of the disease may become 
manifest either in childhood or adulthood. Patients with DOK7 mutations show predominant limb-
girdle weakness, facial weakness and mild ptosis while the extra-ocular muscles are usually 
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spared. These patients do not benefit from AChE inhibitor therapy but they can be treated with 
ephedrine [52] or albuterol [30].  
 
2.2.3.5 SCN4A and PLEC mutations 
Only one CMS patient with mutations in the gene SCN4A encoding the voltage-gated sodium 
channel of skeletal muscle (Nav1.4) has been observed so far [53]. Recently, four CMS patients 
have been reported with mutations in the PLEC gene coding for the intermediate filament-linking 
protein plectin [54-56].   
 
2.3 Therapeutic strategies for CMS 
 
Dependent on a precise molecular genetic diagnosis, there are some strategies for therapy of 
CMS available. These are based on whether the underlying genetic defect decreases or increases 
the synaptic response to ACh. Acetylcholinesterase (AChE) inhibitors are used to increase the 
synaptic response to ACh. When the synaptic response to ACh is attenuated, 3,4-diaminopyridine 
(3,4-DAP) is also a beneficial treatment as it increases ACh release [36]. By contrast, if the AChR 
opening is prolonged, followed by an increased synaptic response, drugs like ephedrine, quinidine 
or fluoxetine are the treatment of choice. Under this condition, the use of AChE-inhibitors is 
ineffective or symptoms might even get worse.  
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Molecular defect  Treatment Reference 
     
Presynaptic defects    
Choline acetyltransferase deficiency  
(CHAT mutation) AChE inhibitors [24-26] 
     
Synaptic  defects    
Endplate AChE deficiency (COLQ mutation)  Ephedrine or albuterol [29] or [30] 
Laminin beta2 subunit (LAMB2 mutation) Ephedrine [31] 
     
 
Postsynaptic defects    
AChR deficiency without kinetic abnormality AChE inhibitors; 3,4-
diaminopyridine plus AChE 
inhibitors 
[57, 58] 
Fast-channel syndrome AChE inhibitors and 3,4-
diaminopyridine 
[59, 60] 
 
Slow-channel syndrome Fluoxetine, Quinidine [61, 62] 
Rapsyn (impaired AChR clustering)  AChE inhibitors  [63] 
MuSK  Ephedrine and 3,4-
diaminopyridine 
[45-47] 
Agrin  Ephedrine [43, 44] 
Sodium channel, voltage-gated (SCN4A mutation) AChE inhibitors and 
acetazolamide 
[53] 
Plectin 3,4-diaminopyridine [64] 
Dok-7  Ephedrine or albuterol [52] or [30] 
 
 
Table 1: Treatment of CMS with different molecular genetic diagnoses        
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3 Novel clinical and molecular entity  
3.1 Limb-girdle (LG-) CMS with frequent tubular aggregates and 
GFPT1 mutations  
3.1.1 LG-CMS symptoms 
LG-CMS patients show shoulder and pelvic girdle weakness and fatigue. No or only minimal 
involvement of ocular and facial muscles is observed. The onset of the disease usually occurs in 
the first decade of life. Repetitive nerve stimulation (RNS) reveals a significant decrement in 
proximal muscles. The majority of patients show tubular aggregates (TAs) in skeletal muscle and 
esterase inhibitor treatment is beneficial for the patients [65, 66]. Unlike patients with GFPT1 
mutation, CMS patients with DOK7 mutation who suffer from limb-girdle weakness as well do not 
benefit from ACh esterase inhibitor treatment and they show involvement of eye movements 
[48].      
 
3.1.2 Tubular aggregates  
Tubular aggregates (TAs) were first described by Engel as granular “crystal-like” inclusions in 
skeletal muscles, associated with mitochondrial aggregates [67]. To date, the presence of TAs 
has been described in the skeletal muscle of patients with a wide range of neuromuscular 
disorders. The mechanisms which underlie the formation of TAs are still unknown. In addition, 
their functional significance in skeletal muscle has not been fully understood and it is unknown 
whether they represent pathological structures or compensatory reactions to diverse pathogenic 
events such as periodic paralysis, dyskalaemia, intoxication, inflammatory myopathies, cramps 
and myalgias, myotonia congenita, familial myopathies, and several other myopathies of 
uncertain etiology [68, 69]. TAs are composed of long tubules containing one or more inner 
tubules and some saccular dilations [69]. By light microscopy, the aggregates can be seen as 
dark inclusions in the nicotinamide-adenine dinucleotide (NADH) stain of muscle biopsies and as 
they stain positive with the NADH-tetrazolium reductase reaction, they were initially thought to 
originate from mitochondria. However, work of several groups has shown that TAs rather arise 
from the sarcoplasmatic reticulum [70].     
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3.1.3 GFPT1 
The enzyme glutamine-fructose-6-phosphate transaminase (GFPT) catalyses the first and rate 
limiting step of the hexosamine biosynthetic pathway (HBP) leading to UDP-GlcNAc production. It 
is highly conserved among species and it is encoded by the two highly homologous genes GFPT1 
and GFPT2 [71, 72] which are localized on different chromosomes (in humans: GFPT1 maps to 
chromosome 2p13-p1 while GFPT2 maps to chromosome 5q34-q35). There are also differences 
in the expression pattern. Both genes are ubiquitously expressed but while GFPT1 is highly 
expressed in the testis, pancreas and placenta, GFPT2 is more abundant in the heart and central 
nervous system [72]. In skeletal and heart muscle, an additional GFPT1 splice variant was 
discovered [73]. The so called GFPT1-L or muscle-specific variant has a 54 base pair insertion 
(additional muscle-specific exon; 18 amino acid insertion) and is more abundant in muscle than 
the shorter ubiquitous splice variant GFPT1 [73]. 
The GFPT enzyme consists of three catalytic domains: the N-terminal 27 kDa glutamine 
amidotransferase domain, which transfers amide nitrogen from glutamine to the substrate 
fructose-6-phosphate, and the two C-terminal sugar isomerase domains which are phosphosugar-
binding domains [74-76]. The bacterial counterpart (GlmS) has been purified to homogeneity and 
extensively structurally analysed [76-79]. The Escherichia coli (E.coli) GlmS enzyme is supposed 
to function as a dimer. The glutamine amidotransferase and sugar isomerase domains are 
connected by a linker and a hydrophobic channel responsible for ammonia transfer between the 
domains. The overall structure of human GFPT1 is similar to the structure of GlmS and the amino 
acid sequence of the isomerase domain of GFPT1 has 43 % identity with GlmS [80]. Recent 
studies on the human GFPT1 enzyme revealed that it exists in at least two different 
oligomerization states (symmetric dimer and tetramer) during the reaction process [80, 81]. 
 
3.2 Hexosamine biosynthetic pathway (HBP)   
 
Cellular glucose is rapidly phosphorylated to glucose-6-phosphate (glucose-6-P) by hexokinases, 
trapping the glucose within the cell. There are multiple pathways for the cellular fate of glucose 
including glycolysis, glycogen synthesis, pentose phosphate pathway and the HBP. The majority 
enters the glycolytic pathway and serves as energy source. Only 2-3 % of total cellular glucose is 
metabolized via the HBP (Figure 3) [82-84].    
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Figure 3: The hexosamine biosynthetic pathway (HBP) and protein O-GlcNAc modification. 
After phosphorylation of glucose to glucose-6-phosphate (glucose-6-P) it is converted to fructose-6-phosphate 
(fructose-6-P) which is metabolized to glucosamine-6-phosphate by glucosamine-fructose-6-phosphate 
aminotransferase 1 (GFPT1). The major end product of the HBP is uridine diphosphate N-acetylglucosamine 
(UDP-GlcNAc). UDP-GlcNAc serves as substrate for uridine-diphospho-N-acetylglucosamine:polypeptide β-N-
acetylglucosaminyltransferase (OGT), leading to the formation of O-linked β-N-acetylglucosamine (O-GlcNAc) 
modified proteins. The figure was adapted and modified from [85].  
 
Glucosamine-fructose-6-phosphate aminotransferase 1 (GFPT1) catalyses the first and rate 
limiting step of the hexosamine biosynthetic pathway (HBP) by converting fructose-6-phosphate 
to glucosamine-6-phosphate with glutamine as amine donor [86]. The metabolization of 
glucosamine-6-P, via different hexosamine intermediates, leads to the formation of uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc). GFPT1 activity is subject to feedback inhibition 
by the end product of the pathway UDP-GlcNAc and has been shown to be regulated by glucose 
in cultured rat adipocytes [87]. Kinetic differences between GFPT1 and GFPT1-L enzyme activities 
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are known. The major kinetic difference is a greater susceptibility of GFPT1-L to feed-back 
inhibition by UDP-GlcNAc [73, 88]. UDP-GlcNAc is a substrate of uridine-diphospho-N-
acetylglucosamine:polypeptide β-N-acetylglucosaminyltransferase (OGT) for the synthesis of 
glycoproteins, glycolipids, proteoglycans and it is the donor for the formation of O-GlcNAc 
modified proteins [89]. The removal of O-GlcNAc from proteins is catalysed by the enzyme β-N-
acetylglucosaminidase (O-GlcNAcase).  
The modification of nuclear and cytoplasmatic proteins by O-GlcNAc is very dynamic and plays a 
role in the alteration of activity [90], function [91], protein stability [92, 93] and subcellular 
localization of target proteins [94-96]. Since some serine and threonine residues modified by O-
GlcNAc are also subject to phosphorylation, GlcNAc is in some cases in direct competition with 
phosphorylation [97].   
In contrast, classical and complex N- and O-linked glycosylation occurs on membrane-bound or 
secreted proteins that are synthesized in the endoplasmic reticulum (ER) and the Golgi 
apparatus.   
   
3.2.1 Glycosylation 
More than 20 posttranslational modifications (PTMs) of proteins are known that occur in 
eukaryotes [98]. The dynamically regulated phosphorylation of proteins might be the most 
studied form. But there are many others including the modification of proteins by addition of 
carbohydrate moieties (glycosylation).  Nearly  half  of  all  proteins are estimated to be  
glycosylated, making  glycosylation  the  most  common  form  of  posttranslational modification 
in  vivo [99]. N-linked glycosylation is characterized by remarkably long chains of carbohydrates 
whereby the carbohydrates are added to secreted proteins at the consensus sequence Asn-X-
Ser/Thr, (where X can be any amino acid except proline) [99, 100]. O-linked glycosylation does 
not require a consensus sequence and is often restricted to a few carbohydrate units [101].  
However, it may be elaborated to great lengths and structural diversity. Classical and complex N- 
and O-linked glycosylation occurs on membrane-bound or secreted proteins during their 
synthesis and transport through the endoplasmic reticulum (ER) and the Golgi apparatus.  
 
3.2.1.1 O-GlcNAc Glycosylation 
The attachment of the monosaccharide β-N-acetylglucosamine (O-GlcNAc) to serine and 
threonine residues of nuclear and cytoplasmatic proteins is a rapid and dynamic modification 
[102, 103]. First described by Hart and Torres in 1984 in lymphocyte cells [103], O-GlcNAc is 
distinguished from  other  classical forms of glycosylation  by  occurring  predominantly  on 
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intracellular  proteins  rather  than  those  secreted  to  membrane  compartments [102]. 
Furthermore, unlike other carbohydrate modifications, but similar to phosphorylation, the 
attachment of O-GlcNAc appears to be dynamically regulated. Since some serine and threonine 
residues modified by O-GlcNAc are also subject to phosphorylation, GlcNAc is in some cases in 
direct competition with phosphorylation [97]. Recent studies revealed that O-GlcNAc levels are 
strongly upregulated in response to a number of cell stress stimuli [104]. It has been shown that 
the global extent of O-GlcNAc modification is tightly dependent of the flux through the 
hexosamine biosynthetic pathway (HBP) [105].   
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E Objectives 
 
Since 1998, our laboratory has collected DNA and clinical data of more than 900 independent 
CMS patients of various ethnic origins. Molecular genetic analysis and characterization of these 
patients led to the identification of numerous disease-causing mutations in known CMS genes 
providing novel insights into synaptic function. The main aspect of this thesis was the 
identification and characterization of genetic alterations which lead to defects in neuromuscular 
transmission at the neuromuscular junction and thereby to CMS. The analysis of the pathology of 
mutations is the basis for the classification of the syndrome and has direct impact on the clinical 
management of CMS patients. 
 
The aim of the first part of this thesis was the identification of the underlying gene defect in LG-
CMS with frequent tubular aggregates. Using genome-wide homozygosity mapping and DNA 
sequencing of positional candidate genes, mutations in GFPT1 were identified in a unique 
collection of LG-CMS families. 
 
The second aim of my thesis was the molecular genetic analysis of the GFPT1 gene in additional 
LG-CMS patients to characterize unsolved CMS patients molecular genetically and to establish 
genotype-phenotype correlations. 
 
In contrast to other CMS genes, GFPT1 is a ubiquitous enzyme expressed in most tissues. 
Consequently, one challenge of the present thesis was to understand how mutated GFPT1 results 
in a selective vulnerability of the NMJ and leads to LG-CMS. To address this question, the 
subcellular localization, enzyme activity and expression levels of GFPT1 carrying LG-CMS causing 
missense mutations were studied. 
 
Furthermore, I aimed to analyse in more detail a peculiar change in the 3’- untranslated region 
(UTR) of GFPT1: c.*22C>A which leads to reduced GFPT1 levels in patient muscle samples. To 
get a hint whether reduced protein amounts resulted from repression of translation or altered 
mRNA stability, real-time qRT-PCR, in silico investigation and experimental validation of miRNA 
binding sites were employed. 
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F Materials and Methods   
 
1 Materials 
1.1 Laboratory equipment  
 
Camera: Zeiss AxioCam HR photo camera (Zeiss, Oberkochen, Germany) 
 
Centrifuges: Centrifuge 5417, 5417R (Eppendorf, Hamburg, Germany); Varifuge 3.0R (Heraeus, 
Buckinghamshire, UK) 
 
Cell culture incubator (37°C): Functional line (Heraeus, Buckinghamshire, UK) 
 
ELISA: Spectra Max 250 microplate reader (Molecular Devices, Sunnyvale, CA) 
 
-80°C Freezer: HERA freeze (Heraeus, Buckinghamshire, UK) 
 
Gel documentation system: Herolab, Wiesloch, Germany 
 
37°C Incubator/ bacteria: Heraeus Instruments (Heraeus, Buckinghamshire, UK) 
 
Laminar airflow cabinet: BDK, Sonnenbühl-Genkingen, Germany 
 
Luminometer: Berthold Technologies TriStar LB 941 
 
Microscope: Zeiss Axiovert 200 M fluorescence microscope (Zeiss, Oberkochen, Germany) 
 
pH-meter: HI9321 Microprocessor pH Meter (Hanna Instruments, Kehl am Rhein, Germany) 
 
Pipetes: Pipetman, Gilson (2 μl, 20 μl, 200 μl, 1000 μl) 
 
Power supply: Bio-Rad Power Pac Basic (Bio-Rad Laboratories, Hercules, USA) 
Proteingel chamber: Bio-Rad Mini Protean II (Bio-Rad Laboratories, Hercules, USA) 
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Software: Photoshop CS2 (Adobe); Illustrator CS2 (Adobe); ImageJ (national institute of health, 
USA) 
 
Spectrophotometer: Nanodrop ND-1000 (PeqLab, Erlangen, Germany) 
 
Thermocycler: Mastercycler personal (Eppendorf, Hamburg, Germany); CFX96 Real-Time System 
(Bio-Rad Laboratories, Hercules, USA) 
 
Western blot imager: ChemoCam Imager (INTAS, Göttingen, Germany)  
 
1.2 Chemicals  
 
All used chemicals were purchased from Sigma-Aldrich, PAA Laboratories or Roth.  
Exceptions are listed below: 
Agarose (Invitrogen); dNTPSet (Fermentas); Fluorescence Mounting Medium (Dako); Horse 
Serum (Invitrogen); Running Buffer (MP Biomedicals, LLC); Transfer Buffer (MP Biomedicals, 
LLC)    
    
1.3 Kits and enzymes   
 
The following enzymes and kits were used: 
Restriction endonucleases with 10x restriction buffer system (NewEngland BioLabs, Roche, 
Fermentas); AccuPrimeTM Pfx DNA Polymerase (Invitrogen); PfuULTRATM High-Fidelity DNA 
Polymerase (Agilent Technologies, Inc.); T4 DNA Ligase (NewEngland BioLabs); Calf Intestine 
Alkaline Phosohatase (Fermentas); RNeasy Kit (Qiagen); RNeasy MinElute Cleanup Kit (Qiagen); 
miRNeasy Kit (Qiagen); miScript PCR Starter Kit (Qiagen); Hs_miR-600_1 miScript Primer Assay 
(Qiagen); Oan-miR-206* miScript Primer Assay (Qiagen); BCA Protein Assay Reagent Kit (Pierce); 
Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH); NucleoSpin Extract II (MachereyNagel); 
NucleoBond PC 500 (MachereyNagel); Dual-Luciferase® Reporter Assay (Promega); Restriction 
endonucleases (NewEngland BioLabs, Fermentas); M-MuLV RT (Fermentas); Polyplus jetPEI 
transfection reagent (Biomol); FuGene6 transfection reagent (Roche Diagnostics); Lipofectamine 
2000 transfection reagent (Invitrogen); Wizard® Genomic DNA Purification Kit (Promega); RNase-
Free DNase Set (Qiagen) 
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1.4 Plasmids  
  
Plasmids Description Supplier 
pCMVmyc 1. E. coli origin of replication for plasmid propagation in E. coli  
2. ampicillin resistance marker for selection of E. coli transformants  
3. mammalian expression vector (CMV promoter)                            
4. allows to express a protein of interest fused to the c-Myc tag              
5. multiple cloning site (MCS) 
Clontech 
pCMVmycL-GFPT1wt pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 wt fragment this study 
pCMVmycT15A pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 T15A fragment this study 
pCMVmycD348Y pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 D348Y 
fragment 
this study 
pCMVmycR434H pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 R434H 
fragment 
this study 
pCMVmycD43V pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 D43V fragment this study 
pCMVmycM492T pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 M492T 
fragment 
this study 
pCMVmycI121T pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 I121T 
fragment 
this study 
pCMVmycR385H pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 R385H 
fragment 
this study 
pCMVmycR111C pCMVmyc vector containing a EcoRI/NotI digested L-GFPT1 R111C 
fragment 
this study 
pEGFP-N1 1. E. coli origin of replication for plasmid propagation in E. coli         
2. kanamycin resistance marker for selection of E. coli transformants  
3. mammalian expression vector (CMV promoter)                            
4. allows to express a protein of interest fused to EGFP                                    
5. multiple cloning site (MCS) 
Clontech 
pCMVL-GFPT1wt pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 wt fragment 
this study 
pCMVT15A pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 T15A fragment 
this study 
pCMVD348Y pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 D348Y fragment 
this study 
pCMVR434H pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 R434H fragment 
this study 
pCMVD43V pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 D43V fragment 
this study 
pCMVM492T pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 M492T fragment 
this study 
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pCMVI121T pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 I121T fragment 
this study 
pCMVR385H pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 R385Hfragment 
this study 
pCMVR111C pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 R111C fragment 
this study 
pCMVL-
GFPT13'UTRwt 
pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 100bp 3'UTR wt fragment 
this study 
pCMVL-c*22C>A pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested L-GFPT1 100bp 3'UTR c*22C>A fragment 
this study 
pCMVGFPT13'UTRwt pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested GFPT1 100bp 3'UTR wt fragment 
this study 
pCMVc*22C>A pEGFP-N1 vector with removed EGFP open reading frame and containing a 
KpnI/NotI digested GFPT1 100bp 3'UTR c*22C>A fragment 
this study 
pRLTK 1. E. coli origin of replication for plasmid propagation in E. coli         
2. ampicillin resistance marker for selection of E. coli transformants  
3. mammalian expression vector (HSV-TK promoter)                           
4. encodes the Renilla luciferase enzyme 
Promega 
pRL-1xG wt pRLTK vector containing a XbaI digested 1xG wt fragment in the 3'UTR 
region of the Renilla luciferase enzyme 
this study 
pRL-1xA mut pRLTK vector containing a XbaI digested 1xA mut fragment in the 3'UTR 
region of the Renilla luciferase enzyme 
this study 
pRL-4xG wt pRLTK vector containing a XbaI digested 4xG wt fragment in the 3'UTR 
region of the Renilla luciferase enzyme 
this study 
pRL-4xA mut pRLTK vector containing a XbaI digested 4xA mut fragment in the 3'UTR 
region of the Renilla luciferase enzyme 
this study 
pGL4.26 1. E. coli origin of replication for plasmid propagation in E. coli         
2. ampicillin resistance marker for selection of E. coli transformants  
3. mammalian expression vector (minP promoter)                            
4. encodes the Firefly luciferase enzyme 
Promega 
pENTR-EF1-mir155 1. E. coli origin of replication for plasmid propagation in E. coli         
2. kanamycin resistance marker for selection of E. coli transformants  
3. mammalian expression vector  
4. the pre-miRNA cloning site is flanked on either side with sequences from 
murine miR-155 to allow proper processing of the engineered pre-miRNA 
sequence 
Sirion 
pEF1-miR-600 pENTR-EF1-mir155 vector containing ds miR-600 oligo wihtin the AaRI site this study 
 
Table 2: Overview of plasmids  
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1.5 Antibodies 
1.5.1 Primary antibodies 
Primary antibody  Supplier Host Dilution 
anti-RL2 O-linked N-Acetylglucosamine IgM Abcam mouse WB: 1:1000 
anti-GFPT1 IgG ProteinTech Group, Inc rabbit WB: 1:1000 
anti-GFP  IgG Abcam rabbit WB: 
1:10000 
anti-alpha-tubulin  IgG Cell Signaling rabbit WB: 1:1000 
anti-beta-actin  IgG Santa Cruz goat WB: 1:200 
anti-c-Myc  IgM Clontech mouse WB: 1:100 
IF: 1:100 
anti-GAPDH IgM Millipore mouse WB: 1:5000 
 
Table 3: Overview of primary antibodies 
 
1.5.2 Secondary antibodies 
Secondary antibody  Conjugate Supplier Host Dilution 
anti-rabbit  HRP Jackson ImmunoResearch goat 1:10000 
anti-goat  HRP Sigma rabbit 1:10000 
anti-mouse HRP DAKO rabbit 1:10000 
anti-mouse IgG Alexa Fluor 488 Invitrogen goat  1:500 
 
Table 4: Overview of secondary antibodies 
 
1.6 E.coli strains 
Strain Genotype Supplier 
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 
araD139 Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG λ- 
Invitrogen 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
Invitrogen 
 
Table 5: Overview of strains 
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1.7 Nucleic acids 
1.7.1 Solution 
Real-time PCR reaction mix:  
QuantiTect SYBR Green PCR Master Mix (Qiagen, Hilden, Germany) 
SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, USA) 
 
1.7.2 Size standards 
1 kb ladder: GeneRuler™ 1 kb DNA ladder (Fermentas) 
100 bp ladder: GeneRuler™ 100 bp DNA ladder (Fermentas) 
 
1.7.3 Oligonucleotides for molecular genetic analysis of putative GFPT1 
patients 
Oligonucleotide primer Sequence 
GFAT1s 5'-GAGGGAGTCGTGTCGGC-3' 
GFAT1as 5'-CATCACCCAGACTTCGCAC-3' 
GFAT2s 5'-TGAAATGTTTGAAAGACAGAATCTAAC-3' 
GFAT2as 5'-GCAATACTCCACATAAATGGTAACAC-3' 
GFAT3s 5'-TATCCTGGTTCTTGACACACAATAG-3' 
GFAT3as 5'-TTTCTTTCCTCCCTTCAATGTTAC-3' 
GFAT4s 5'-GTATATTCCAAGAGAGCAGCATTG-3' 
GFAT4as 5'-TGCTCTCTACTACTTCTGAATGTTTG-3' 
GFAT5s 5'-ACTGTTTGCTTCAGCTATGCCAC-3' 
GFAT5as 5'-TATGGTGTTTGTTGCACATCCC-3' 
GFAT6s 5'-TTTGAATAATGGGATATGGTGTTC-3' 
GFAT6as 5'-CTAATCCTCCATCGTGTGTACTGTG-3' 
GFAT7s 5'-AAGCCAGTATGTTCTAGGCATTTC-3' 
GFAT7as 5'-TAAATGGAAGAGTGGTAAGCAACAG-3' 
GFAT8s 5'-TCTTATATCTGAAGTTGAGCTTGGG-3' 
GFAT8as 5'-ATCTGACCAAAGAGCCATCTATTC-3' 
GFAT9s 5'-CATGGAAATAAGGTGATCTACTTGG-3' 
GFAT9as 5'-AGACTGATACACAATGACTTCTTGG-3' 
GFAT10s 5'-TCTGAGATACTGCAGAGTGATAGAG-3' 
GFAT10as 5'-CTAGCGTTGTCCCTTCACTAATC-3' 
GFAT11s 5'-TTTAGGCAGTCATGTCTATTGC-3' 
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GFAT11as 5'-AGTTGTTCTACAAGGCTATTAAGGG-3' 
GFAT12s 5'-ATTGCCTAGTTCACATGGTTCTTTG-3' 
GFAT12as 5'-CCATGGATAAATAATTCCAAGCAG-3' 
GFAT13s 5'-AAGTCCGATGAAAGAGTATTTGAAG-3' 
GFAT13as 5'-AATCTGTATTCGTCAAGTCATCTGC-3' 
GFAT14s 5'-AGGAAGAGAGATCCTGACAAGCC-3' 
GFAT14as 5'-TTAAACTCTATCAGGAAGAGGGAG-3' 
GFAT15s 5'-ACAGGGTCTCACTCTGTCCCAG-3' 
GFAT15as 5'-CTAAATAGCTACAAGCCACAGCTTC-3' 
GFAT16s 5'-ACCCATACTGATTGATAGCACAGAG-3' 
GFAT16as 5'-CAATGCATAAATACAGAAGCACTTTC-3' 
GFAT17s 5'-TTTGGATAGATAGACAGTGGCTTG-3' 
GFAT17as 5'-ATGTAAACCTCAAAGGCTGTATTCC-3' 
GFAT18s 5'-CCTGGTATTTCTTAGTTGCATGAG-3' 
GFAT18as 5'-GTGATGTAACCTACAAATTGGGC-3' 
GFAT19s 5'-CTCTTTCTGTGTGAACTGGCAC-3' 
GFAT19as 5'-TAGATTCCATTATTCAAAGTCCTCC-3' 
GFAT8Amss 5'-GGAATAGATGGCTCTTTGGTCAG-3' 
GFAT8Amsas 5'-GCACATTCATTCACTCCAAGAAC-3' 
 
Table 6: Overview of GFPT1 exon oligonucleotides 
 
1.7.4 Oligonucleotides for cDNA amplification 
Oligonucleotide primer Sequence 
KpnIGFPT1_for 5'-TATTAGGTACCCGCCACCATGTGTGGTATATTTGCTTACTTAAAC-3' 
EcoRIGFPT1_for 5'-GCGAATTCTGATGTGTGGTATATTTGCTTACTTAAAC-3' 
NotIGFPT1_rev 5'-GCGGCCGCTCACTCTACAGTCACAGATTTGG-3' 
NotIGFPT13UTR_rev 5'-TTGATGCGGCCGCGTCCTCCACAAATTACTGGGAAAATG-3' 
 
Table 7: Overview of cDNA amplification oligonucleotides 
 
 
 
 
 
 
 
Marina Dusl  MATERIALS AND METHODS 
 
30 
 
1.7.5 Oligonucleotides for site-directed mutagenesis PCR 
Oligonucleotide primer Sequence 
GFAT1_R111C sense 5'-GTCAATAGCCACCCCCAGTGCTCTGATAAAAATAATGA-3'  
GFAT1_R111C antisense 5'-TCATTATTTTTATCAGAGCACTGGGGGTGGCTATTGAC-3' 
GFAT1_T15A sense 5'-AACTACCATGTTCCTCGAGCGAGACGAGAAATCCT-3' 
GFAT1_T15A antisense 5'-AGGATTTCTCGTCTCGCTCGAGGAACATGGTAGTT-3' 
GFAT1_D43V sense 5'-TCTGCTGGTGTGGGATTTGTTGGAGGCAATGATAA-3' 
GFAT1_D43V antisense 5'-TTATCATTGCCTCCAACAAATCCCACACCAGCAGA-3' 
GFAT1_I121T sense 5'-AGCGCTCTGATAAAAATAATGAATTTATCGTTACTCACAATGGAATCATCA-3' 
GFAT1_I121T antisense 5'-TGATGATTCCATTGTGAGTAACGATAAATTCATTATTTTTATCAGAGCGCT-3'  
GFAT1_ D348Y sense 5'-ATGAGAGGAAGAGTCAACTTTGATTACTATACTGTGAATTTGGG-3' 
GFAT1_ D348Y antisense 5'-CCCAAATTCACAGTATAGTAATCAAAGTTGACTCTTCCTCTCAT-3' 
GFAT1_ R434H sense 5'-GATACTTTGATGGGTCTTCATTACTGTAAGGAGAGAGGA-3' 
GFAT1_ R434H antisense 5'-TCCTCTCTCCTTACAGTAATGAAGACCCATCAAAGTATC-3' 
GFAT1_ M492T sense 5'-TGATGTTTGCCCTTATGACGTGTGATGATCGGATCTC-3' 
GFAT1_M492T antisense 5'-GAGATCCGATCATCACACGTCATAAGGGCAAACATCA-3' 
GFAT1_R385H sense 5'-ATCATGAAGGGCAACTTCAGTTCATTTATACAGAAGGAAATATTTG-3' 
GFAT1_ R385H antisense 5'-CAAATATTTCCTTCTGTATAAATGAACTGAAGTTGCCCTTCATGAT-3' 
GFAT1_c.*22 sense 5'-GTGAGGAATATCTATACAAAATGTAAGAAACTGTATGATTAAGCAACACAA-3' 
GFAT1_c.*22 antisense 5'-TTGTGTTGCTTAATCATACAGTTTCTTACATTTTGTATAGATATTCCTCAC-3' 
 
Table 8: Overview of mutagenesis oligonucleotides 
 
1.7.6 Oligonucleotides for plasmid sequencing 
Oligonucleotide primer Sequence 
pCMVs 5'-ACTTTCCAAAATGTCGTAACAACTC-3' 
pCMVas 5'-ACCACAACTAGAATGCAGTGAAAA-3' 
GFAT1_600bp_for 5'-ATTGGTGTACGGAGTGAACATAAAC-3' 
pCMVmyc_for 5'-GATCCGGTACTAGAGGAACTGAAAAAC-3' 
pCMVmyc_rev 5'-ATAGCATCACAAATTTCACAAATAAAG-3' 
pENTRs 5'-CCTACGTCGAGCAGCACGAGATG-3' 
pRLTKs 5'-GGTCTTCATTTTTCGCAAGAAG-3' 
 
Table 9: Overview of plasmid sequencing oligonucleotides 
 
 
Marina Dusl  MATERIALS AND METHODS 
 
31 
 
1.7.7 Oligonucleotides for cloning of the miR-600 expression plasmid 
miR single strand 
nucleotides 
sequence 
miR-600_top 5'-TGCTGACTTACAGACAAGAGCCTTGCTCGTTTTGGCCACTGACTGA 
CTAGGAAGGCTCTTGTCTGTCAGG-3' 
miR-600_bottom 5'-CCTGCCTGACAGACAAGAGCCTTCCTAGTCAGTCAGTGGCCAAAAC 
GAGCAAGGCTCTTGTCTGTAAGTC-3' 
 
Table 10: Overview of miR-600 oligonucleotides 
 
1.7.8 Oligonucleotides for qRT-PCR 
Oligonucleotide primer Sequence 
GFPT1 for 5'-AACACAGTTGGCAGTTCCAT-3' 
GFPT1 rev 5'-GCATGATCTCTTTGCGTCTT-3' 
hH4 for 5'-GGTGACTTACACGGAGCAC-3' 
hH4 rev 5'-ACCGCCGAAACCATAAAG-3' 
 
Table 11: Overview of qRT-PCR oligonucleotides 
 
All primers were designed with Primer3 program, synthesized and ordered at Metabion 
(Martinsried, Germany). The miScript Primer Assays for real-time PCR in order to detect the 
mature miRNAs hsa-miR-600 and oan-miR-206* were ordered at Qiagen (Hilden, Germany).  
 
1.7.9 Mature siRNAs/miRNAs/inhibitors and control miRNA 
Oligonucleotide Supplier 
hsa-miR-600-MSY0003268                5‘-ACUUACAGACAAGAGCCUUGCUC-3‘ Qiagen 
anti-hsa-miR-600-MIN0003268 Qiagen 
oan-miR-206*-MSY0006994              5‘-ACAUGCUUCUUUAUAUCCCCA-3‘ Qiagen 
siRNA Gfpt1-MSS204659                   5‘-UAUCCAAGAAGUCACUGGCAAGCUC-3‘ Invitrogen 
miRNA control-1027280 Qiagen 
 
Table 12: Overview of miRNAs, inhibitors, controls and siRNAs  
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As hsa-miR-206* was not annotated, assays were performed using oan-miR-206* after checking 
sequence homology using http://www.mirbase.org/.  
 
1.8 Patients 
1.8.1 Collection of genomic DNA samples 
Venous blood samples were obtained from the patients as well as from their unaffected relatives, 
if available. All studies were carried out with informed consent of the patients or their parents.  
All samples that were collected were assigned an identification number. 
 
2 Methods 
2.1 Patient selection 
 
The patients were selected for the molecular genetic analysis of GFPT1 according their clinical 
picture and – for linkage studies – according to the pedigree structure. This subgroup of CMS 
patients is characterized by proximal muscle weakness and fatigue. The majority showed tubular 
aggregates in muscle biopsies but additional CMS patients without tubular aggregates, and 
patients with non-fatigable weakness but with tubular aggregates were included as well. A 
common feature was a beneficial response to acetylcholinesterase inhibitor treatment, while the 
patients showed only minimal ocular and facial involvement [65, 66]. Most of the patients had 
been tested negative for DOK7 mutations.   
   
2.2 Microbiology methods 
2.2.1 Preparation of competent cells 
E. coli bacteria from glycerol stocks were streaked out on LB plates and incubated o.n. at 37°C. 
One single colony was used to grow a 5 ml LB preculture o.n. at 37°C. About 16 h later, 2 ml of 
the preculture was transferred into 1 l LB medium and grown to an OD600 of 0.5 (about 2-3 h). 
The culture was cooled on ice for 10 min and centrifuged (10 min, 4000 rpm, 4°C). After 
centrifugation, the supernatant was discarded and the cell pellet was resuspended in 300 ml ice 
cold TFBI. Cells were incubated on ice for 30 min and centrifuged at 4000 rpm for 5 min (4°C). 
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The pelleted cells were gently resuspended in 40 ml ice cold TFBII. Aliquots of 200 μl were 
stored at -80°C. 
 
Luria-Bertani (LB) medium 
1.0 % bacto-tryptone 
1.0 % NaCl 
0.5 % bacto-yeast extract 
pH 7.0 with 10 M NaOH 
 
The medium was autoclaved and after cooling down to 60°C the appropriate antibiotics were 
added. For preparing plates the LB medium was mixed with 1.5 % agar. 
 
TFBI 
30 mM KAcetate 
100 mM KCl 
50 mM MnCl2 
15 % glycerol 
pH 5.8 
filter 0.2 μm, keep at 4°C 
 
TFBII 
10 mM MOPS/NaOH pH 7 
75 mM CaCl2 
10 mM KCl 
15 % glycerol 
filter 0.2 μm, keep at 4°C 
 
2.2.2 Plasmid transformation 
Chemically competent cells were thawed on ice and plasmid DNA or ligation product was added. 
The cell suspension was incubated on ice for 30 min, heat-shocked for 30 sec at 42°C and 
immediately chilled on ice for 2 min. 250 μl of SOB medium was added and the cells were 
incubated for 1 h at 37°C. The transformed cells were plated on LB agar plates supplemented 
with the appropriate antibiotic and incubated for 12 to 16 h at 37°C. 
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Super Optimal Broth (SOB) medium 
2 % bacto-tryptone  
0.5 % bacto-yeast extract  
8.56 mM NaCl  
2.5 mM KCl  
0.01 mM MgCl2 
pH 7.0 with 10 M NaOH 
The medium was sterilized in an autoclave. 
 
2.2.3 Culturing of E. coli 
E. coli cells were grown in LB medium, supplemented with appropriate antibiotic if indicated, at 
37°C with constant shaking at 200 rpm. In order to isolate single colonies, cells were plated onto 
LB agar plates containing appropriate antibiotic if indicated. 
 
2.2.4 Isolation of plasmid DNA from E. coli 
2.2.4.1 Miniprep 
LB medium (5 ml) supplemented with the appropriate antibiotic was inoculated with a single 
colony picked from an agar plate of transformed bacteria. The cultures were grown at 37°C and 
shaking at 200 rpm o.n. 4 ml of each o.n. culture were transferred into a tube and centrifuged (5 
min, 14000 rpm). The pelleted bacteria were resuspended in 250 μl P1 to destabilize the bacterial 
membrane. The bacterial suspension is lysed by adding 250 μl P2. To mix the components, the 
tubes were immediately inverted several times and incubated at rt for 3 min. The lysis was 
stopped by adding 350 μl P3 immediately followed by inverting the tube again several times and 
incubating on ice for at least 10 min. Chromosomal DNA and precipitated proteins were 
sedimented by centrifugation (10 min, 14000 rpm). The supernatant was transferred in a 1.5 ml 
tube. Isopropanol (600 μl) was added and the sample was centrifuged 30 min at 14000 rpm 
(4°C). The pelleted plasmid DNA was washed twice with 70 % ethanol and centrifuged (5 min, 
13000 rpm, 4°C). The supernatant was discarded and the pellet air dried. The dried DNA was 
rehydrated in an appropriate volume of TE buffer. 
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P1 
50 mM Tris pH 8.0 
10 mM EDTA 
100 μg/ml RNase A 
 
P2 
200 mM NaOH 
1 % SDS 
 
P3 
3 M KAcetate pH 5 
 
TE buffer 
10 mM Tris-HCl  
1 mM EDTA 
pH 8.0 
 
2.2.4.2 Maxiprep 
In order to obtain larger amounts of plasmid DNA, 250 ml of LB medium including the 
appropriate antibiotic were inoculated with 150 μl of a single colony preculture. The culture was 
incubated at 37°C at 200 rpm in a shaker (o.n.). The bacterial suspension was transferred into a 
corning tube and the bacteria were pelleted by centrifugation (15 min, 3500 rpm, 4°C). The 
further isolation of the plasmid DNA was done with the NucleoBond PC 500 kit according to the 
manufacturer`s instructions. 
 
2.3 Nucleic acid methods 
2.3.1 Genomic DNA isolation from whole blood samples 
Total genomic DNA was isolated from leukocytes of whole blood samples by means of a salting-
out method using a blood and tissue culture DNA extraction kit (Wizard Genomic DNA Purification 
Kit, Promega) according to the manufacturer’s recommendations. 
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2.3.2 Agarose gel electrophoresis 
For qualitative as well as quantitative analysis, the DNA was separated by size on an agarose gel 
containing ethidium bromide. The percentage of agarose solution ranged from 1 to 4 % in 1x 
TAE buffer. For high percentage gels (4 %) 10 % ethanol (80 %) was added to the 1x TAE 
buffer. The agarose solutions were boiled and allowed to cool down to approximately 50°C. 
Afterwards ethidium bromide was added to a final concentration of 0.1 μg/ml.  
Before loading the samples onto the gel they were mixed with 6x loading dye. Gel electorphoresis 
was performed with 10 V/cm gel length. 1 kb or 100 bp ladder were used as a size standard. The 
DNA was visualized by UV light. Gels were documented with the help of a gel documentation 
system. 
 
1x TAE 
0.049 M Tris  
2 mM EDTA 
Acetic acid glacial pH 8.5 
 
6x loading dye 
10 mM Tris-HCl pH 7.6 
0.03 % Bromphenol blue 
60 % Glycerol 
60 mM EDTA 
 
2.3.3 Gel purification 
For DNA gel purification, the NucleoSpin Extract II Kit was used. In brief, the desired DNA band 
was excised from the gel and the gel slice was dissolved in appropriate buffer at 50°C. The DNA 
was supplied onto the column, provided with the kit. After a washing step, the DNA was eluted in 
an appropriate volume of TE buffer and stored at -20°C.  
 
2.3.4 Quantification and purity analysis of DNA 
The concentration and the purity of solutions of plasmid DNA, PCR products after purification via 
agarose gels or isolated DNA from blood samples were determined with a NanoDrop ND-1000 
spectrophotometer by measuring the absorption at 260 nm. 
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2.3.5 Cloning of the miRNA expression plasmid  
The pENTR-EF1-mir155 (SIRION BIOTECH, Martinsried, Germany) vector was used to create the 
pEF1-miR-600 expression plasmid. The pre-miRNA cloning site is flanked on either side with 
sequences from murine miR-155 to allow proper processing of the engineered pre-miRNA 
sequence. Two complementary single-stranded DNA oligonucleotides encoding the hsa-miR-600 
were designed containing a 5’ overhang (TGCT or CAGG) (Table 10) complementary to the vector 
and required for directional cloning. The synthetic oligonucleotides were synthesized and 
purchased at Metabion (Martinsried, Germany). After annealing, the double-stranded (ds) oligos 
were directly cloned into the AarI site of the pENTR-EF1-mir155 vector. Orientation of the insert 
was verified by sequencing. 
 
2.3.6 Polymerase Chain Reaction (PCR) 
2.3.6.1 Exon-specific PCR 
After isolation of total DNA from blood of putative CMS patients, PCR was used to amplify known 
coding exons, the adjacent intronic regions as well as the promoter region of CMS genes. 
 
Standard reaction: 
      
Component                                                                  Amount per reaction 
ddH2O ad 50 μl 
10xThermoPol buffer 5 μl 
mM each dNTPs  0.25 
Forward primer  50 pmol 
pmol Reverse primer  50 
gDNA template  100-500 ng 
U Taq 2.5 
Total reaction volume 50 μl 
 
        
Temperature                                                                                Time                     Cycles 
95°C 2 min   
95°C   15 sec   
59°C 1 min     40x  
72°C 2 min   
72°C 7 min   
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The calculation of the melting temperature (Tm) according to the nearest neighbor method was 
done as described by [106] but using the values published by [107]. For this purpose the 
Oligonucleotide Properties Calculator OligoCalc by [108] available at 
http://www.basic.northwestern.edu/biotools/oligocalc.html was used. 
The PCR products were analysed on an agarose gel in order to control the amplification of the 
DNA fragments by agarose gel electrophoresis. The required band was excised from the gel, 
purified and sequenced. 
 
2.3.6.2 cDNA amplification PCR 
Human GFPT1 cDNA was amplified from human skeletal muscle cDNA and inserted into the 
EcoRI and NotI sites of the pCMV-Myc vector allowing expression of human GFPT1 with an N-
terminal Myc-tag. For enzyme activity assays, the GFPT1 constructs were cloned into the pEGFP-
N1 plasmid. Simultaneously the EGFP open reading frame was removed to obtain untagged 
GFPT1. For expression studies, the human GFPT1 coding region and additional 100 bp of the 3’ –
UTR was amplified from human skeletal muscle cDNA and inserted into the KpnI and NotI sites of 
the pEGFP-N1 plasmid (Clonetech, Mountain View, CA). The EGFP open reading frame was 
removed to obtain untagged GFPT1.  
 
Standard reaction: 
      
Component                                                                   Amount per reaction  
ddH2O Ad 50 μl 
10xPfuUltra HF reaction buffer 5 μl 
mM each dNTPs 0.25  
Forward primer  50 pmol 
pmol Reverse primer  50 
DNA template (500ng/μl) 1 μl 
PfuUltra HF DNA Polymerase 1 μl 
Total reaction volume 50 μl 
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Temperature                                                                                 Time                Cycles 
95°C 2 min   
95°C 30 sec   
49°C 30 sec 5x  
72°C 1-3 min   
95°C 30 sec   
53°C 30 sec 20x  
72°C 1-3 min   
72°C 7 min   
     
All PCR samples were analysed on an agarose gel. The required band was excised from the gel, 
purified, digested and ligated in the appropriate digested vector. Ligated plasmid DNA was 
directly transformed into Escherichia coli cells. Correct orientation of the inserts and absence of 
PCR-induced mutations were verified by sequencing. 
 
2.3.6.3 Site-directed mutagenesis PCR 
The GFPT1 mutants T15A, D348Y, R434H, D43V, M492T, I121T, R385H, R111C and *22C>A 
were generated by site directed mutagenesis [109] with mismatch primers (Table 8). In brief, 
two mutant fragments were amplified and purified. In the following steps the fragments were 
annealed and extended. After purification of the extended mutant fragment it was digested and 
ligated into the appropriate digested vector. Ligated plasmid DNA was directly transformed into 
Escherichia coli cells. Correct orientation of the inserts and absence of PCR-induced mutations 
were verified by sequencing. 
 
2.3.6.4 Colony PCR 
Colony PCR was used to screen single bacterial colonies by PCR in order to determine if they 
have inserted the transformed plasmid DNA.  
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Standard reaction: 
      
Component                                                                      Amount per reaction  
ddH2O ad 50 μl 
10xThermoPol buffer 5 μl 
dNTPs 0.25 mM each 
Forward primer  50 pmol 
Reverse primer 50 pmol 
μl Bacterial suspension  2 
Taq 2.5 U 
Total reaction volume 50 μl 
    
 
      
Temperature                                                                                Time                Cycles 
95°C 6 min   
95°C 30 sec   
40x  55°C 30 sec 
72°C 1-3 min   
72°C 7 min 
  
 
All PCR samples were analysed on an agarose gel and plasmid DNA from positive colonies was 
isolated by miniprep. The orientation of the insert and absence of polymerase chain reaction-
induced mutations were verified by sequencing. 
 
2.3.6.5 Reverse transcription (RT)-PCR 
Total RNA was extracted from cells or human muscle using RNeasy kit according to the 
manufacturer‘s manual. In case of human muscle, the protocol was adjusted. The tissue (about 
30 mg) was pestled under liquid nitrogen at least 15 min prior to the homogenization step in 
QIAzol. To avoid DNA contamination, on column DNaseI digestion was performed. The cDNA was 
dissolved in RNase-free water. RNA concentration was quantified using a spectrophotometer. 
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Standard reaction for total and large RNA:  
      
Component                                                                   Amount per reaction 
RNase free H2O ad 20 μl 
ng RNA 500 
5x reaction buffer  4 μl 
RiboLock RNase inhibitor 20 U 
dNTPs 1 mM 
U Reverse transcriptase 20 
Random hexamer primers 1 μl 
Total reaction volume 20 μl 
 
 
 
Temperature                                                                               Time 
25°C 10 min 
37°C 60 min 
70°C 10 min 
4°C   hold 
 
The cDNA was used for qRT-PCR, amplification of specific genes (end-point PCR) or stored at -
20°C. 
 
In order to extract and separate into small (miRNA) and large RNA (mRNA), the miRNeasy Kit 
was combined with the RNeasy MinElute Cleanup Kit according to the manufacturer‘s manual.  
RNA was dissolved in RNase-free water (small RNA in 14 μl; large RNA in 45 μl) and the 
concentration of the large RNA fraction was quantified using a spectrophotometer. 
 
Standard reaction for small RNA using the miScript PCR Kit: 
      
Component                                                                    Amount per reaction  
RNase free H2O 3.5 μl 
μl RNA (MinElut) 3 
5x reaction buffer  2 μl 
Nucleic mix 1 μl 
Reverse transcriptase mix 0.5 μl 
Total reaction volume 10 μl 
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Temperature                                                                               Time 
37°C 60 min 
95°C 5 min 
4°C  hold 
 
The cDNA was used for qRT-PCR or stored at -20°C. 
 
2.3.6.6 Quantitative real-time PCR (qRT-PCR) 
For mRNA, the desired target cDNA species were amplified using specific primers. The primer 
pairs for mRNA expression (Table 11) were designed using published sequences (GFPT1: 
NM_002056.3; hH4: NM_175054.2). They were ordered and synthesized at Metabion 
(Martinsried, Germany). To correct for sample to sample variation, an endogenous control, hH4, 
was amplified with the target and served as an internal reference to normalize the data. The 
expression levels of GFPT1 relative to those of hH4 were calculated using the 2-ΔΔCT method 
[110]. 
 
Standard reaction: 
      
Component                                                                    Amount per reaction  
RNase free H2O ad 20 μl 
cDNA 12.5 ng 
μl 2x SensiFAST SYBR no-ROX Mix 10 
Forward primer (10µM) 0.8 μl 
Reverse primer (10µM) 0.8 μl 
Total reaction volume 20 μl 
 
The reaction plates were centrifuged for 2 min at 3000 rpm to abolish bubbles. 
        
Temperature                                                                                Time                Cycles 
95°C 2 min   
95°C 5 sec   
60°C 10 sec 40x  
72°C 10 sec   
65-95°C     0.5°C steps 
 
For miRNA, the miScript Primer Assay for specific miRNA targets were synthesized and ordered at 
Qiagen. MicroRNA was quantified by a two-step real-time PCR using the miScript-Reverse 
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Transcripton kit combined with the miRNA-SYBR Green PCR kit. Cellular miRNA levels were 
normalized using U6 snRNA (RNU6) as reference RNA. The amount of miR-600, miR-206 and 
miR-206* relative to RNU6 was calculated using the 2-ΔΔCT method [110]. For the qRT-PCR 96-
Well Optical Reaction Plates (BioRad) were used. 
 
Standard reaction using the miScript PCR system: 
      
Component                                                                   Amount per reaction  
RNase free H2O 5 μl 
cDNA 16.7 ng 
μl 2x QuantiTec SYBR Green 10 
10x UP primer 2 μl 
10x primer assay primer 2 μl 
Total reaction volume 20 μl 
 
The reaction plates were centrifuged for 2 min at 3000 rpm to remove bubbles. 
 
       
Temperature                                                                               Time                  Cycles 
95°C 15 min   
94°C 15 sec   
55°C 30 sec 40x  
70°C 30 sec   
65-95°C     0.5°C steps 
 
All PCR samples were analysed on a 4 % agarose gel. 
 
2.3.7 Restriction digest 
For analytic restriction, about 400 ng of DNA were digested using 5 U of each restriction enzyme 
in a total volume of 20 µl. Double digests were performed using the appropriate NEB buffer to 
achieve the highest possible activity for the combination of both enzymes. Bovine serum albumin 
(BSA) was added if required. Restriction digest was performed for 2 h at 37°C.  
For cloning purposes, 2 µg of DNA were digested using 10 U of enzyme for 2 h at 37°C. BSA was 
added if required. The linearized plasmid was dephosphorylated with 1 U Calf Intestine Alkaline 
Phosohatase (CIAP) in CIAP buffer for 30 min at 37°C to prevent re-ligation. Afterwards the 
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phosphatase was inactivated for 10 min at 65°C. The sample was purified via NucleoSpin Extract 
II Kit according to the manufacturer´s protocol. 
 
2.3.8 Ligation 
Ligation of digested plasmids and PCR fragments was performed with T4 DNA ligase. Reaction 
mixtures contained plasmid and PCR fragment (insert) in a molar ration of 1:3. Usually 100 ng of 
plasmid were used. The mass of insert to be used was calculated according to the following 
equation:  
 
mass (insert) = 3 ∙ mass (plasmid) ∙      
number of bp (insert) 
                number of bp (plasmid) 
 
      
Component                                                                                    Amount per reaction  
ddH2O ad 10 μl 
ng Plasmid 100 
Insert 3-fold molar amount of plasmid    
T4 DNA ligase  1 μl 
T4 DNA reaction buffer (10x)  1 μl 
Total reaction volume 10 μl 
 
The reaction mix was pipetted at rt and incubated o.n. in an isolating box in the cold room (4°C). 
 
2.3.9 Sequencing of DNA 
The sequencing of purified DNA premixed with primer was performed by Eurofins MWG Operon 
(Ebersberg, Germany). 
 
2.3.10 Genome-wide linkage analysis 
Homozygosity mapping [111] was performed by genome-wide genotyping of SNP for family 
LGM3 using the Illumina 300 K chip (Illumina, San Diego, CA). Multipoint linkage analysis was 
performed with MERLIN [112]. DNA samples from families LGM1, LGM2, LGM5, LGM6, LGM7, 
LGM8, LGM10, LGM11, and LGM12 were analyzed with short tandem repeat (STR) markers. 
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Twenty-three markers were retrieved from the National Center for Biotechnology Information 
UniSTS database, and four new polymorphisms were identified by using the Repeat-Masker 
program. PCR primers for new STRs were designed by the Primer3 program. The sense primers 
were labeled with FAM fluorophores (MWG Biotech, Ebersberg, Germany) for detection on an ABI 
377 DNA sequencer (Applied Biosystems, Foster City, CA). Multipoint LOD scores were calculated 
with the GeneHunter v2.1r5 program [113] in the EasyLinkage software package [114]. The 
genomic localization of the markers was derived from the Marshfield map and the University of 
California Santa Cruz (UCSC) human genome assembly. Linkage analysis was performed in 
collaboration with Prof. Dr. Jan Senderek (Aachen, Germany) and Dr. Tim-Matthias Strom 
(Munich, Germany). 
 
2.3.11 Linkage analysis 
In some CMS index patients we used a linkage approach with DNA marker sets of the known 
CMS genes [115] in order to reduce the number of candidate genes prior to subsequent mutation 
analysis. In order to use the patients for linkage analysis, they have to derive from families with 
more than one affected patient or several unaffected siblings and possibly parental 
consanguinity. The microsatellite marker set included the gene loci of the known CMS genes 
CHRNA1, CHRNB1, CHRNE, CHRND, CHAT, COLQ, RAPSN, DOK7, MUSK, SCN4A, AGRN and 
GFPT1. The linkage analysis was performed in collaboration with Prof. Dr. Angela Hübner 
(Dresden, Germany).  
 
2.4 Tissue culture methods 
 
Five different adherent cell lines were used in this study: human embryonic kidney 293 cells 
(HEK293), skeletal mouse myoblasts C2C12, the human adrenal carcinoma cell line SW13, the 
african green monkey kidney fibroblast cell line COS-7 and human myoblasts. All cell lines were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) except for 
human myoblasts (Muscle Tissue Culture Collection, Friedrich-Baur-Institute, Munich, Germany). 
 
2.4.1 General information  
HEK293, C2C12, SW13 and COS-7 cells were cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10 % fetal calf serum, 2 mM Glutamine and penicillin/ streptomycin 
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(40 U/mL penicillin and 0.04 mg/mL streptomycin).  Primary human myoblasts were isolated as 
previously described [116]. Myoblasts from patients with GFPT1 mutations and control myoblasts 
were obtained from the Medical Research Council (MRC) Centre for Neuromuscular Diseases 
Biobank, Newcastle, UK, and the Muscle Tissue Culture Collection, Friedrich-Baur-Institut, 
Munich, Germany. Human myoblasts were grown in skeletal muscle growth medium (SGM 
PromoCell, Heidelberg, Germany) supplemented with SupplementalMix (Provitro), 10 % FCS, 1.5 
% 100 x Glutamax (Gibco) and 50 μg/ml gentamycin. For maturation into multinucleated 
myotubes, the human myoblasts were grown in SGM on culture dishes coated with laminin 
(Sigma) to near confluency. They were induced to fuse and differentiate by replacing SGM with 
DMEM supplemented with 5 % horse serum (fusion medium) for 7 d. All cell lines were kept in a 
37°C incubator with a humidified atmosphere of 5 % CO2. 
 
2.4.2 Passage of cells 
The cells were grown in 10 cm or 16 cm tissue culture dishes and washed once with PBS before 
digestion with 0.05 % trypsin-EDTA for about 5 min at 37°C. The trypsin digest was terminated 
by adding supplemented DMEM or SGM medium.   
 
2.4.3 Transfection of HEK293, SW13, COS-7 or C2C12 cells  
Cells were plated in 10 cm tissue culture dishes, 6-well plates, 24-well plates or on cover slips the 
day before transfection and grown to 60-90 % confluency. HEK293 cells were transfected with 3–
6 mg of wild-type and mutated GFPT1 plasmid DNA (with and without N-terminal Myc tag) with 
Polyplus jetPEI transfection reagent (Biomol, Hamburg, Germany) according to the 
manufacturer’s recommendations. Transfection of SW13 cells was carried out with FuGene6 
transfection reagent (Roche Diagnostics, Mannheim, Germany). C2C12 cells were transfected 
with 3 μg of GFPT1-3’-UTR wt or mutant (c.*22C>A) constructs. The cells were co-transfected 
with 0.3 μg pEGFP-N1 (Clontech, Mountain View, CA) in order to use the expression of the green 
fluorescent protein (GFP) as a transfection efficiency control. Lipofectamine (Invitrogen, Carlsbad, 
CA) was used according to manufacturer’s instructions. Cells were analyzed 24-48 h after 
transfection by immunoblot, immunofluorescence staining or GFPT1 activity assay. 
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2.4.4 siRNA experiments 
C2C12 cells were plated in 6-well plates the day before transfection and grown to a confluency of 
50 %. The siRNA duplex oligonucleotides (100 pmol) (Table 12) were diluted in Lipofectamine 
according to manufacturer’s instructions. The mixture was added drop by drop to the cells and 
they were analyzed 24 h after transfection by immunoblot. 
 
2.4.5 Harvesting of cells 
Growth medium was removed using a vacuum pump and cells were washed with sterile PBS. The 
cells were mechanically scraped in ice cold 1xPBS buffer and transferred to a 1.5 ml tube. After 
centrifugation at 14000 rpm at 4°C (5 min) the supernatant was removed and the cell pellet was 
used for protein isolation or stored at -80°C. 
 
2.4.6 Storage of cells 
Cells were grown to 80-90 % confluency in 10 cm tissue culture dishes and washed once with 
PBS before digestion with 0.05 % trypsin-EDTA for about 5 min at 37°C. The trypsin digest was 
terminated by adding supplemented DMEM medium. The cell suspension was transferred to a 50 
ml falcon tube and centrifuged for 3 min at 1200 rpm (RT). The cell pellet was resuspended in 2 
ml freezing medium, transferred to a 2 ml freezing vials and gently cooled down to -80°C. The 
frozen cells were stored in liquid nitrogen.  
To utilize cells in culture, they were quickly thawed, washed with medium (3 min, 1200 rpm, RT) 
and seeded in a 10 cm dish for further culturing. 
 
Freezing medium 
DMEM medium 
10 % DMSO 
30 % FCS 
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2.5 Protein methods 
2.5.1 Protein isolation 
For Western blot analysis, protein extracts from different cell lines were used. Cells were 
harvested 24 or 48 h after transfection. The cells were washed once with 1xPBS buffer, 
mechanically scraped in 1x PBS buffer and transferred to a 1.5 ml tube. After centrifugation at 
14,000 rpm at 4°C for 5 min the supernatant was removed and the cell pellet was homogenized 
in lysis buffer. Homogenized cell samples were then incubated at 95°C for 5min. Debris was 
removed by 5 min centrifugation at 14,000 rpm and supernatants were used for immunoblot 
analysis. 
 
Lysis buffer  
10 mM Tris-HCl pH 7.4 
1 % SDS 
 
2.5.2 Protein quantification 
Protein concentrations were determined using the BCA Protein Assay (Pierce) or the BioRad 
Protein Assay according to the manufacturer`s instruction. BSA (Bovine serum albumin) was 
used as a protein standard [117]. 
 
2.5.3 SDS-Polyacrylamid-Gelelectrophoresis (SDS-PAGE) 
Discontinuous electrophoresis was used to separate protein mixtures. The gel consists of an 8 % 
separating and a 3.3 % stacking gel that were poured sequentially. After complete polymerization 
of the gel it was placed into a chamber filled with SDS running buffer. The protein samples were 
mixed with SDS loading dye and denatured for 5 min at 95°C before applying on the gel. Protein 
markers were used to determine the molecular weight of the samples. Proteins were separated at 
120 V.  
Afterwards the gel was further processed by Western blotting. 
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Lower Tris (4x) 
36.34 g Tris base 
8 ml 10 % SDS 
ad 200 ml H2O 
pH 8.8 
 
Upper Tris (4x) 
6.06 g Tris base 
4 ml 10 % SDS 
ad 100 ml H2O 
pH 6.8 
 
Separating gel (8 %) 
4.83 ml H2O 
2.67 ml acrylamid mix (30/0.8) 
2.5 ml Lower Tris 
50 μl 10 % APS 
10 μl TEMED 
 
Stacking gel (3.3 %) 
3.25 ml H2O 
0.55 ml acrylamid mix (30/0.8) 
1.25 ml Upper Tris 
20 μl 10 % APS 
10 μl TEMED 
 
Running buffer 
25 mM Tris 
192 mM glycine 
0.1 % SDS 
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SDS loading dye (6x) 
20 mM Tris-HCl pH 6.8 
6 % SDS 
30 % glycerol 
0.03 % bromphenol blue 
5 % β-Mercaptoethanol 
 
2.5.4 Western blotting 
A nitrocellulose membrane (BioTrace™ NT Nitrocellulose Transfer Membrane; 9 cm x 6 cm; 0.20 
μm pore size; PALL) as well as two filter papers and two fiber pads were pre-wet in transfer 
buffer. The gel was removed from the electrophoresis apparatus and the blotting sandwich was 
assembled in the following order: gel holder cassette (white side; facing the positive electrode), 1 
fiber pad, 1 piece of filter paper, membrane, gel, 1 piece of filter paper, 1 fiber pad, gel holder 
cassette (black side; facing the negative electrode). The assembly was transferred to the blotting 
apparatus, which was filled with 1 x transfer buffer and an ice block for cooling. The proteins 
were transferred to the membrane by electrophoresis at 110 V for 2 h at 4°C.  
In order to determine the blotting efficiency the membrane was Ponceau S stained after the 
transfer and washed in 1xTBS-T for 20 min. The membrane was blocked in 5 % milk/BSA in 1x 
TBS-T for 1 h at rt on a shaker. Subsequently it was incubated with the primary antibody in 5 % 
milk/BSA in TBS-T o.n. at 4°C on a shaker followed by five washing steps (5 min each) in TBS-T. 
Afterwards the membrane was incubated with the appropriate HRP conjugated secondary 
antibody for 1 h at 4°C while shaking. The blot was washed again five times and the 
immunoreactive bands were visualised with the ECL system (ECL Advance Western Blotting 
Detection Kit, Amersham) using the ChemoCam Imager of INTAS. 
 
Ponceau S staining solution  
0.1 % Ponceau S  
5 % acetic acid 
 
1x TBS-T 
10 mM Tris-HCl pH 7.4 
140 mM NaCl 
0.1 % Tween-20 
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Transfer buffer 
25 mM Tris 
192 mM glycine 
0.02 % SDS 
15 % methanol 
 
2.5.5 Immunofluorescence 
For immunofluorescence analysis, cells were grown on glass coverslips and transfected as 
described above. Fortyeight hours after transfection, coverslips were washed in PBS, fixed in 3.7 
% formaldehyde (freshly prepared from paraformaldehyde) in 1x CSK buffer for 10 min at room 
temperature, and permeabilized with 0.1 % Triton X-100 in 1x CSK buffer for 15 min. After three 
washes in PBS, nonspecific binding sites were blocked with PBS containing 5 % horse serum for 
1 h, followed by overnight incubation at 4°C with the appropriate primary antibody in PBS with 5 
% horse serum. After three washes in PBS, cells were incubated with the secondary antibody, for 
1 h at room temperature. Nuclei were visualized with bisbenzimide H 33258 (40 mg/ml). Digital 
images were captured with a Zeiss Axiovert 200 M fluorescence microscope and a Zeiss AxioCam 
HR photo camera. 
 
1x CSK buffer  
100 mM NaCl  
300 mM sucrose  
3 mM MgCl2  
1 mM EGTA 
10 mM PIPES  
pH 6.8 
 
2.5.6 GFPT1 enzyme activity assay 
The enzymatic activity of untagged wild-type and mutant GFPT1 was measured with the 
glutamate dehydrogenase method [118, 119]. HEK293 cells transfected with GFPT1 expression 
constructs were lysed in GFPT buffer, and 100 ml aliquots of the lysates were mixed with an 
equal volume of the reaction buffer and incubated at 37°C for 45 min. Glutamate was used as a 
standard. The change in absorbance was monitored at 370 nm with a Spectra Max 250 
microplate reader. The enzymatic activity of each mutant was normalized to GFPT1 expression 
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levels determined by immunoblot analysis of cell lysates used for enzyme activity measurements. 
All transfections and measurements were done in triplicates. 
 
GFPT buffer 
50 mM KH2PO4  
10 mM EDTA   
5 mM reduced L-glutathione  
12 mM D-glucose-6-phosphate Na2  
1 mM PMSF  
pH 7.6 
freshly prepared 
 
Reaction buffer 
100 mM KH2PO4 
10 mM D-fructose 6-phosphate  
6.0 mM L-glutamine  
0.3 mM 3-acetylpyridine adenine dinucleotide  
50 mM KCl  
6 U L-glutamate dehydrogenase from bovine liver  
pH 7.6 
freshly prepared 
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2.5.7 Dual Luciferase reporter assay                                                                                                  
 
Figure 4: Schematic view of the transfection of COS-7 
cells followed by the Dual-Luciferase reporter assay 
 
The pRL-TK (Promega, Madison, WI) reporter vector 
containing a wt and mutant (c.*22C>A) 80 bp 
fragment of the GFPT1 3’-UTR or multimers of it 
(Figure 28) was used as reporter assay in COS-7 
cells. The four tandem repeats of an 80 bp 
sequence (GeneArt, Carlsbad, CA) encompassing wt 
or mutant c.*22C>A predicted miRNA binding site 
were cloned into the XbaI restriction site 
downstream from the Renilla luciferase (RLuc) gene. 
An empty Firefly luciferase reporter vector (pGL4, 
Promega) was used as control. 0.8 x 105 cells per 
well in 24-well plates were transfected using 
Polyplus jetPEI transfection reagent (Biomol, 
Hamburg, Germany) following manufacturer’s 
recommendations with a mixture comprising 200 ng 
of pRL-TK construct, 2 ng of pGL4 control vector 
and the appropriate mature miRNA mimic (hsa-miR-
600, oan-miR-206*; Qiagen, Hilden, Germany) or control miRNA (100 nM; Qiagen, Hilden, 
Germany). For blocking experiments 300 nM αmiRNA-600 (Qiagen, Hilden, Germany) were 
included. 24 h after transfection, luciferase expression was analysed using the dual-luciferase 
reporter assay system (Promega, Madison, WI).  In brief, cells were rinsed once with 1xPBS and 
lysed with 1xPLB. In order to assure complete lysis, cell lysates were incubated on a shaker at 
200 rpm for 15 min. The Firefly reporter is measured first by adding Luciferase Assay Reagent II 
to generate a luminescent signal. After quantifying this luminescence, the reaction is quenched, 
and the Renilla luciferase reaction is simultaneously initiated by adding Stop & Glo Reagent. In 
order to correct for vector-dependent unspecific effects and to correct for differences in the 
transfection efficiency, relative reporter activity was obtained by normalization to Firefly luciferase 
activity (ratio of Renilla luciferase to Firefly luciferase). Each experimental condition was 
measured in triplicates and each assay was performed three times. Dual luciferase assay was 
performed on white 96-well plates using 20 μl lysate and 100 μl of both substrates per well. 
Luciferase expression was detected on a Berthold Technologies TriStar LB 941 reader. As hsa-
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miR-206* was not annotated, assays were performed using oan-miR-206* after checking 
sequence homology using http://www.mirbase.org/.  
 
2.6 Statistical analysis 
 
The data show the mean ± SD. Statistical significance was determined with two-tailed Student’s 
t-test. Significance was set at p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***). 
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G Results 
 
1 Identification of GFPT1 mutations in LG-CMS families 
 
LG-CMS patients, characterized by weakness of limb muscles, sparing of ocular or facial muscles, 
good treatment response to acetylcholinesterase inhibitors and tubular aggregates (TA) in muscle 
biopsy samples were analysed by a genome-wide linkage screen in order to identify the 
molecular defect causing this condition.  
 
1.1  Selection of LG-CMS families for molecular genetic studies  
 
Using direct sequencing or haplotype analysis we had previously excluded all known genes and 
loci known to be involved in CMS (CHRNA1, CHRNB1, CHRND, CHRNE, CHAT, COLQ, DOK7, 
RAPSN, MUSK, SCN4A, LAMB2, AGRN as well as two functional candidate genes CNTN1 and 
AChE) in the 16 LG-CMS families analysed in this study. 
 
1.1.1 Clinical features of LG-CMS families 
Sixteen LG-CMS families (comprising 23 patients) of various ethnic origins were selected for 
molecular genetic studies.  
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Figure 5: Summary of the clinical features of 23 LG-CMS patients. 
LG: limb-girdle; RNS: repetitive nerve stimulation; AChE: acetylcholine esterase; TA: tubular aggregate 
 
All patients presented with limb-girdle weakness and patients who had a neurophysiological 
examination showed a decremental response in repetitive nerve stimulation (RNS). Almost all 
patients (95 %) responded well to AChE-inhibitor therapy. Tubular aggregates (TAs) were 
identified in the muscle biopsies of 75 % of the LG-CMS patients. Only few patients had facial 
weakness (23 %) and only 5 % of the patients showed respiratory weakness. Ocular muscles 
were generally spared: None of the patients showed involvement of the external eye muscles 
(ophthalmoparesis) and only 5 % exhibited ptosis.   
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1.1.2 Pedigree analysis 
Pedigrees of the LG-CMS families included in the study: 
 
 
 
 
 
Figure 6: Pedigrees of the limb-girdle myasthenia (LGM) families included in the study. 
Circles represent females, squares males and diamonds were used when the information on the gender was 
unknown. A double line indicates a consanguineous marriage. Filled symbols represent affected family members. 
Red bars indicate the individuals of whom genomic DNA was obtained and used for genotyping. Asterisks indicate 
patients whose clinical data were available. 
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Family Ethnic origin Consanguinity 
LGM1 Iran + 
LGM2 Turkey + 
LGM3 Libya + 
LGM4, 13, 15, 16 Italy 4: +; 13, 15, 16: - 
LGM5 Spain - 
LGM6 Germany - 
LGM7 UK - 
LGM8 UK - 
LGM9 Germany - 
LGM10 Senegal + 
LGM11 Spain + 
LGM12 Spain - 
LGM13 Italy - 
LGM14 Sweden - 
LGM15 Italy - 
LGM16 Italy - 
 
Table 13: Summary of the ethnic origin and the marriages of the 16 limb-girdle myasthenia (LGM) 
families. +: yes; -: no 
 
The families are of various ethnic origins from nine different countries (Table 13). There is almost 
equal frequency of the disease in both sexes (female and male). LGM families LGM1-4, LGM10 
and LGM11 are consanguineous (Figure 6 and Table 13). All parents of the patients are healthy. 
In total, the genomic DNA of 62 individuals was used for genotyping, of whom 23 were affected 
and clinical data was available (Figure 6). 
All in all, the genetic evaluation of the LG-CMS families revealed pedigrees typical of an 
autosomal recessive trait of the disease (Figure 6).  
 
1.2 Genome-wide homozygosity mapping 
 
Genome-wide homozygosity mapping in an extended pedigree of a consanguineous Libyan family 
(LGM3, Figure  6) with five affected children allowed to identify the genetic locus for LG-CMS. 
The homozygosity mapping in this family defined a single candidate region on chromosome 2 
(2p12-p15) with a maximum LOD score (logarithm (base 10) of odds) of 3.24. A LOD score >3 is 
usually considered sufficient for establishing genetic linkage to a chromosomal region. Using 
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linkage and homozygosity data from additional, smaller pedigrees (LGM1, 2, 5, 6, 7, 8, 10, 11, 
12) the critical interval was narrowed down to a region of interest of 5.92 Mb. The genes in this 
region (46 genes) were prioritized on the basis of expression pattern and function. They were 
evaluated and ranked with respect to neuromuscular endplate and skeletal muscle biology and 
disease or role in calcium metabolism (tubular aggregates seen in muscle biopsies of LG-CMS 
patients might be a consequence of calcium overload) or vesicle transport.    
 
Gene name GenBank Mutation analysis 
MEIS1 NM_002398 yes 
ETAA1 NM_019002 no 
C1D NM_001190265 no 
WDR92 NM_138458 yes 
PNO1 NM_020143 no 
PPP3R1 NM_000945 yes 
CNRIP1 NM_001111101 no 
PLEK NM_002664 yes 
FBXO48 NM_001024680 no 
APLF NM_173545 no 
PROKR1 NM_138964 yes 
ARHGAP25 NM_001007231 yes 
BMP10 NM_014482 no 
GKN2 NM_182536 no 
GKN1 NM_019617 no 
ANTXR1 NM_032208 no 
GFPT1 NM_002056 yes 
NFU1 NM_015700 yes 
AAK1 NM_014911 yes 
ANXA4 NM_001153 yes 
GMCL1 NM_178439 no 
SNRNP27 NM_006857 no 
MXD1 NM_002357 yes 
ASPRV1 NM_152792 no 
LOC400960 NR_033872 no 
PCBP1 NM_006196 no 
C2orf42 NM_017880 no 
TIA1 NM_022173 no 
PCYOX1 NM_016297 no 
SNRPG NM_003096 no 
FAM136A NM_032822 no 
TGFA NM_003236 yes 
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Table 14: Positional candidate genes in the defined LG-CMS candidate region (chromosome 2p12-
p15; region of interest of 5.92 Mb) 
 
None of the 46 genes had been previously associated with CMS or is exclusively expressed at the 
NMJ or in motor neurons or in skeletal muscle. Therefore, the entire coding region and exon-
intron boundaries of 16 genes (Table 14; mutation analysis: yes) were sequenced in the index 
patients of three families (LGM1, 3, 10).  
Fifteen genes were sequenced before different homozygous missense mutations were identified 
in the glutamine—fructose-6-phosphate transaminase 1 (GFPT1) gene in all three families. No 
disease-related sequence changes were identified in any of the other sequenced genes. Further 
evidence for a causative role of GFPT1 mutations in LG-CMS where achieved when extending the 
mutation screening to additional families in our cohort. Mutations were identified in all LG-CMS 
families except for LGM4, 15 and 16. GFPT1 mutations had not previously been linked to a 
human disease.   
 
1.3 GFPT1 mutation spectrum  
 
GFPT1 is the first and rate-limiting enzyme in the hexosamine biosynthetic pathway (HBP) 
leading to UDP-GlcNAc production. The GFPT1 gene is composed of 19 constitutive exons (1-19) 
and one alternative exon (8A) exclusively incorporated in mRNA encoding the muscle-specific 
GFPT1-L protein. GFPT1 has a total length of 62 kb and is located on chromosome 2p13.  
 
ADD2 NM_017488 yes 
FIGLA NM_001004311 no 
CLEC4F NM_173535 no 
CD207 NM_015717 no 
VAX2 NM_012476 no 
ATP6V1B1 NM_001692 no 
ANKRD53 NM_024933 no 
TEX261 NM_144582 no 
NAGK NM_017567 yes 
MCEE NM_032601 no 
MPHOSPH10 NM_005791 no 
PAIP2B NM_020459 no 
ZNF638 NM_014497 yes 
DYSF NM_001130981 yes 
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Exon Nucleotide change Effect on the protein LG-CMS families with the mutation 
2 c.43A>G p.Thr15Ala LGM13 
2 c.44C>T p.Thr15Met LGM8 
3 c.128A>T p.Asp43Val LGM6 
4 c.222_223insA p.Gln76fs LGM14 
4 c.331C>T p.Arg111Cys LGM3, LGM14 
5 c.362T>C p.Ile121Thr LGM6 
7 c.595G>T p.Val199Phe LGM9 
8 c.621_622 del p.Leu208fs LGM13 
8A c.719G>A p.Trp240X LGM2 
11 c.1042G>T p.Asp348Tyr LGM1 
13 c.1154G>A p.Arg385His LGM7 
14 c.1278_1281 dup p.Asp428fs LGM12 
14 c.1301G>A p.Asp434His LGM7 
15 c.1472T>C p.Met491Thr LGM11 
15 c.1475T>C p.Met492Thr LGM5 
15 c.1486C>T pArg496Trp LGM8 
15 c.1534C>T p.Arg512Trp LGM10 
19 c.*22C>A  LGM5, LGM9, LGM12 
 
Table 15: GFPT1 mutations identified in LG-CMS families.  
No GFPT1 mutations were identified in LGM families LGM4, 15 and 16. The nucleotide and amino acid numbering 
is according to NM_002056.2 and NP_002047.2 (exception c.719G>A (p.Trp240X): AF334737.1 and 
AAK15342.1). 
 
 
 
 
Figure 7: Schematic view of the domain structure of GFPT1 and the positions of the identified 
mutations in 13 LG-CMS families. 
GFPT1 consists of a glutaminase and two sugar isomerase (SIS) domains. The insertion of 18 amino acids (aa) of 
the muscle-specific exon is indicated. Reference sequence: NM_002056.2   
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In total, 18 different GFPT1 mutations consisting of 13 missense mutations, three frameshift 
mutations (p.Gln76fs, p.Leu208fs and Asp428fs), one nonsense mutation (p.Trp204X) and one 
variant in the 3’-UTR (c.*22C>A) were found in 13 unrelated LG-CMS families (Table 15 and 
Figure 7). Mutations are distributed throughout the entire gene and affect the glutaminase as 
well as the sugar isomerase domain (Figure 7). There is only one LG-CMS patient with a 
homozygous-GFPT1 null mutation (LGM2). However, the homozygous p.Trp240X mutation is 
located in the alternative exon, exclusively incorporated in the muscle-specific GFPT1-L protein 
(Figure 7). None of the GFPT1 patients carried two null mutations in the constitutive exons of the 
gene. One of the GFPT1 mutations identified in three independent families from Spain (LGM5 and 
12) and Germany (LGM9) was a nucleotide exchange 22 bp downstream of the TGA translation 
termination codon (c.*22C>A) in the 3’-untranslated region (UTR). In all three families, the 
mutation was compound heterozygous to missense or protein truncating mutations (Table 15).  
 
2 Molecular genetic analysis of isolated LG-CMS patients  
2.1 Clinical features of putative GFPT1 patients of the Munich CMS 
patient cohort 
 
Subsequent to the identification of GFPT1 as novel CMS gene further undiagnosed patients from 
our cohort of about 900 CMS patients were screened for mutations in the GFPT1 gene according 
to their clinical picture and/or haplotype analysis results. 
We primarily selected patients with prominent limb-girdle weakness, tubular aggregates in 
skeletal muscle biopsies and good response to esterase inhibitor therapy. 
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Figure 8: Summary of the clinical features of 15 CMS patients analysed in this study in order to 
identify the underlying molecular genetic defect. 
LG: limb-girdle; RNS: repetitive nerve stimulation; AChE: acetylcholine esterase; TA: tubular aggregates   
 
In total, 15 undiagnosed CMS patients from our CMS cohort were screened for GFPT1 mutations. 
The majority of the patients (73 %) exhibited limb-girdle weakness. If limb-girdle weakness was 
missing, the patients showed at least tubular aggregates in their muscle biopsy and/or haplotype 
analysis suggested potential linkage at the GFPT1 locus. In about 86 %, repetitive nerve 
stimulation (RNS) yielded a decremental response, if electrophysiology was tested (6/7). About 
75 % of the patients responded well to AChE-inhibitor therapy if treated (6/8). Most muscle 
biopsies showed unspecific or mild myopathic changes and tubular aggregates (TAs) were 
identified in 50 % (5/10). Four patients showed only tubular aggregates in muscle biopsies, while 
additional hints for LG-CMS were missing. These patients were included in order to define 
whether only TAs are a sufficient inclusion criteria for LG-CMS with GFPT1 mutations. Only a 
minor proportion of patients exhibited facial weakness (21 %) and none of the patients showed 
respiratory weakness.  
 
2.2 Identified GFPT1 mutations 
 
The following results were obtained by direct sequencing of the coding exons (1-19 and the 
additional muscle-specific exon 8A) and the adjacent intronic regions of the GFPT1 gene in 
additional patients selected as described above. 
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2.2.1 Polymorphisms and harmless variants 
Sequencing of the GFPT1 gene in the 15 CMS patients revealed several known and unknown 
single nucleotide polymorphisms (SNPs) that are unlikely to be disease-related but rather 
represent normal variations among individual genomes.  
  
 
 
 
Figure 9: Map of GFPT1 gene and the locations of the SNPs relative to the coding exons. 
Dark shading indicates coding regions, light shading indicates untranslated regions and introns are shown as a 
line. Large introns are not shown completely (double vertical lines). 
 
 
Name Sequence variation Location dbSNP ID Minor allele frequency 
(MAF) 
SNP1 IVS1+36T>C intron 1 rs6720415 A = 0.38 
SNP2 IVS5+30T>C intron 5 rs67760762 G = 0.26 
SNP3 IVS11+7A>G intron 11 rs6722492 T = 0.39 
SNP4 IVS13+13delT intron 13 rs113734896 - = 0.10 
SNP5 
IVS18-22delTT 
 
intron 18 unknown unknown 
 
Table 16: Summary of the sequence variations found in 15 putative GFPT1 patients.  
Reference sequence: AC114772. IVS: intervening sequence; del: deletion; A: adenine; C: cytosine; G: guanine; 
T: thymine. SNP1, SNP2 and SNP3 are already published in [120, 121]. MAF source: dbSNP. 
 
As the so far identified GFPT1 mutations are found along the coding sequence, all exons were 
sequenced in this study. A total of five sequence variations were identified in 15 putative GFPT1 
patients of our Munich patient cohort (Table 16). All variations are localized in different introns of 
the GFPT1 gene. They do not affect spice sites and they were found in a broad variety of patients 
and controls. The MutationTaster algorithm (http://www.mutationtaster.org) [122] and the 
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Exome Variant Server predicted all variations as polymorphisms. Therefore, they were supposed 
to be single nucleotide polymorphisms (SNPs).  
  
2.2.2 Pathogenic mutations identified in GFPT1 
Putative pathogenic mutations are sequence variations which are assumed to alter different 
protein features and are linked to a human disease. The 15 putative GFPT1 patients were 
sequenced for GFPT1 mutations according to their clinical picture and/or haplotype analysis 
results. The disease co-segregation with recessive inheritance of the GFPT1 mutations was 
analysed if DNA from family members was available.  
 
Exon Nucleotide change Effect on the protein Patient with the mutation 
7 c.572G>T p.Ser191Ile patient 3 
8 c.639G>A p.Ser213Asn patient 1 
12 c.1060G>C p.Gly354Arg patient 2 
15 c.1472T>C p.Met491Thr patient 1 
16 c.1649C>T p.Ala550Val patient 4 
19 c.*22C>A  patient 4 
 
Table 17: GFPT1 mutations identified in 15 putative GFPT1 patients.  
GFPT1 mutations were identified in four of 15 putative GFPT1 patients. The nucleotide and amino acid numbering 
is according to NM_002056.2 and NP_002047.2. 
 
 
 
 
Figure 10: Schematic view of the domain structure of GFPT1 and the position of the identified 
mutations. 
GFPT1 consists of a glutaminase and two sugar isomerase (SIS) domains. The insertion of 18 amino acids (aa) of 
the muscle-specific exon is indicated. Reference sequence: NM_002056.2   
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In total, putative pathogenic GFPT1 mutations were identified in four of 15 unsolved CMS 
patients (Table 17 and Figure 10).  
 
Patient 1 showed limb-girdle weakness, decremental response to RNS and benefited from 
AChE-inhibitors. His muscle biopsy revealed aspecific changes without TAs. This patient carried 
the compound heterozygous mutations c.1472T>C (p.M491T) [65] and c.638G>A (p.S213N). To 
date, the p.S213N mutation localized within the glutaminase domain (Figure 10), has not been 
published but the MutationTaster algorithm (http://www.mutationtaster.org) predicts a “disease 
causing” effect of the mutation on the GFPT1 protein. In addition, the mutation is not listed in 
the Exome Variant Server (http://evs.gs.washington.edu/EVS/). Compound heterozygosity was 
confirmed by analysis of DNA samples of the parents. 
 
Patient 2 showed limb-girdle weakness, no clear effect from AChE-inhibitor therapy and no TAs 
in a biopsy of the muscle. RNS was not tested. The parents of the patient are first cousins. This 
patient carried the homozygous GFPT1 mutation c.1060G>C (p.G354R) which is localized 
between the glutaminase and the SIS1 domain (Figure 10). The MutationTaster algorithm 
(http://www.mutationtaster.org) also predicts a “disease causing” effect of the mutation on the 
GFPT1 protein. The mutation c.1060G>C (p.G354R) is not listed in the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/).  
 
Patient 3 showed limb-girdle weakness, a positive effect from AChE-inhibitor treatment and TAs 
in muscle biopsy. The RNS test revealed no decremental response. In this patient, the 
heterozygous variation c.572G>T (p.S191I) which is localized within the glutaminase domain was 
identified. The MutationTaster algorithm (http://www.mutationtaster.org) predicts a “disease 
causing” effect of the mutation on the GFPT1 protein but no second mutation was identified in 
this patient. The sequence variation c.572G>T (p.S191I) is not listed in the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/). The healthy father of patient 3 also carried the mutation 
heterozygously making autosomal dominant inheritance very unlikely. In order to investigate if 
the patient carries a second mutation not detectable by sequencing of genomic DNA, the cDNA 
reverse transcribed from muscle RNA of the patient was analysed.    
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Figure 11: Gel analysis of the GFPT1 cDNA PCR product of patient 3. 
Gel electrophoresis analysis of the amplicon confirms the presence of one fragment with the expected size (~2.1 
kb). An 1 kb DNA marker was used. Since the GFPT1 and the GFPT1-L transcripts differ only in 54 bp and the 
DNA resolution of the gel (1 % agarose) is low, only one GFPT1 cDNA band, consisting of both transcripts, was 
observed.  
 
Gel analysis of the PCR product showed one GFPT1 cDNA band at about 2.1 kb. This band  
consists of the muscle specific longer isoform GFPT1-L (2.097 kb) and the shorter isoform GFPT1 
(2.045 kb). No truncated transcripts were detected and sequencing of the RT-PCR product did 
not reveal any abnormal exon-exon junctions, largely excluding a second mutation which has an 
effect on splicing.    
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Figure 12: Sequence analysis of cDNA of a control patient (wild-type) and patient 3 carrying GFPT1 
c.572G>T (p.S191I) heterozygously. 
Reverse strand chromatograms are shown.  
 
Sequence analysis of the cDNA fragment amplified from muscle cDNA of patient 3 also showed 
biallelic expression of G and T alleles at position c.572. This finding largely excluded the 
possibility of mutations leading to instable transcripts or the existence of an mRNA that contains 
a premature translation-termination codon (PTC) which could lead to nonsense-mediated decay 
(NMD) of the mRNA. The results suggest that, patient 3 carries a putative pathogenic mutation 
(p.S191I) but without any effect on the patient due to the heterozygous state of the mutation 
and the absence of a second mutation.  
 
Patient 4 showed limb-girdle weakness, benefited from AChE-inhibitor therapy and had no TAs 
in a biopsy of the deltoid muscle. A decremental response was observed in the trapezius muscle. 
This patient carried the compound heterozygous mutations c.*22C>A and c.1649C>T (p.A550V). 
The 3’-UTR mutation c.*22C>A is a recurrent change [65] while the p.A550V variant, localized 
within the isomerase 2 (SIS2) domain (Figure 10), has not yet been published. The 
MutationTaster algorithm (http://www.mutationtaster.org) predicts a “disease causing” effect of 
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the mutation on the GFPT1 protein. The mutation is not listed in the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/). 
 
No GFPT1 mutations were identified in the patients with non-fatigable weakness but with tubular 
aggregates in the muscle biopsies (4/15). 
 
3 Characterization of mutant GFPT1 species 
3.1 Investigation of GFPT1 missense mutations 
 
In total, 21 different GFPT1 mutations consisting of 16 missense mutations, three frameshift 
mutations, one nonsense mutation and one in the 3’-UTR were found in 16 unrelated LG-CMS 
families (Figure 7 and 10). GFPT1 mutations had not previously been linked to a human disease 
and the pathomechanism resulting in NMJ and skeletal muscle dysfunction is currently unclear. In 
order to investigate the role of GFPT1 in CMS pathogenesis, selected missense mutations were 
characterized. First of all GFPT1 protein levels were analysed in myoblast cells of GFPT1 patients. 
After that mutant proteins were transiently expressed in SW13 or HEK293 cells and effects on 
expression levels and subcellular localization were assessed. Finally the enzyme activity of GFPT1 
mutants was measured in vitro.   
 
3.1.1 Expression studies of mutant GFPT1 species 
3.1.1.1 Reduced GFPT1 expression in GFPT1-mutated myoblast cells from GFPT1 
patients  
Primary myoblasts were derived from three GFPT1 patients. The immunoblots were performed to 
establish the GFPT1 protein levels in the myoblast lysates using anti-GFPT1 antibody. 
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Figure 13: Western Blot of GFPT1 and O-GlcNAcylation in myoblast samples of GFPT1 patients. 
Immunoblot was performed on protein samples from primary human myoblasts (MB) obtained from three 
different GFPT1 patients (LGM5.3, 5.5 and 9.3), heterozygous for c.*22C>A, compared to two healthy control 
individuals (ctr1 and ctr2) with an anti-GFPT1 antibody (top). LGM5.3 and 5.5 are compound heterozygous for 
c.*22C>A and c.1475T>C (p.Met492Thr); LGM9.3 is compound heterozygous for c.*22C>A and c.595G>T 
(p.Val199Phe). The RL2 antibody detects single N-acetylglucosamine at serine or threonine residues [123] 
(middle).  The anti-β-actin antibody was used to ensure equal protein loading (bottom).    
 
Western Blot analysis of myoblasts obtained from three GFPT1 patients (LGM5.3, 5.5 and 9.3) 
revealed reduced expression of the mutant GFPT1 protein compared to wild-type controls. 
Furthermore, immunoblotting of protein extracts with the RL2 antibody, which selectively detects 
O-linked N-acetylglucosamine (O-GlcNAc) residues on numerous proteins [123], revealed 
markedly decreased band intensities in myoblasts of GFPT1 patients compared to healthy 
controls. The anti-β-actin antibody visualized equal protein loading (Figure 13).  
 
3.1.1.2 Modulation of GFPT1 affects the levels of O-linked N-acetylglucosamine on 
proteins 
O-GlcNAc, the main product of the hexosamine biosynthetic pathway (HBP) which is regulated by 
GFPT1, is essential for posttranslational modification of serine and threonine residues of nuclear 
and cytoplasmic proteins. Immunoblot analysis of myoblast lysates of GFPT1 patients and 
controls with the RL2 antibody, which selectively detects O-GlcNAc residues on proteins, showed 
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that O-GlcNAcylated proteins were markedly decreased in lysates from the patients’ myoblast 
cells. To examine whether loss of Gfpt1 leads to impaired glycosylation of proteins in cultured 
myoblasts, C2C12 cells were treated with Gfpt1 siRNA to decrease its expression. 
 
 
 
Figure 14: Western Blot of GFPT1 and O-GlcNAcylation in siRNA treated C2C12 cells 
C2C12 cells were treated with control or Gfpt1 siRNA and immunoblotted with an anti-GFPT1 antibody. The RL2 
antibody detects single N-acetylglucosamine at serine or threonine residues [123].  The anti-α-tubulin antibody 
was used to ensure equal protein loading. 
 
Western Blot analyses showed that Gfpt1 siRNA down-regulated endogenous Gfpt1 protein levels 
(Figure 14; Gfpt1 antibody). Silencing with siRNA reduced Gfpt1 protein efficiently (85-90 %) and 
resulted in a reduction of the levels of O-linked N-acetylglucosamine on proteins compared with 
control siRNA (Figure 14; RL2 antibody). 
This experiment also linked reduced amounts of functional Gfpt1 protein to reduced levels of O-
linked N-acetylglucosamine on proteins.  
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3.1.1.3 Transfection studies of wild-type and mutant GFPT1 constructs in HEK293 
cells 
To study the effect of mutations on protein expression levels in a controlled experiment, plasmid 
constructs were generated to express wild-type and mutant myc-tagged GFPT1-L (muscle-
specific variant) protein (p.Arg111Cys, p.Asp43Val, p.Met492Thr, p.Thr15Ala, p.Asp348Thr, 
p.Arg434His and p.Ile121Thr) in HEK293 cells. The cells were co-transfected with the different 
myc-tagged GFPT1 constructs together with a pcDNA3 vector, expressing GFP to estimate 
transfection efficiency. Immunoblot analysis was performed to establish the levels of wild-type 
and mutant myc-tagged GFPT1 protein in HEK293 cells using anti-GFPT1 antibody. 
 
 
Figure 15: Western Blot of GFPT1 in HEK293 cells co-transfected with either the wild-type or 
mutant GFPT1 constructs and GFP. 
The cells were co-transfected with a GFP expression vector for transfection efficiency control.  The cell lysates 
were immunoblotted with an antibody that recognizes the myc-tagged GFPT1 protein. The anti-actin antibody 
was used as loading control and visualized equal protein loading.    
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Figure 16: Expression study 
HEK293 cells were transfected with either wild-type or mutant GFPT1 constructs and GFP. Protein bands (for a 
representative experiment see figure 15) were quantified with the ImageJ program. GFPT1 expression levels were 
normalized to GFP and actin protein amounts. Expression levels of each mutant are compared to that of the wild-
type. Three independent transfection experiments were performed for each mutant and lysates were measured in 
triplicates. Error bars indicate + SD; significant differences from wild-type *P < 0.05.   
 
The amount of myc-tagged GFPT1 protein species was measured by immunoblotting in 
transiently transfected HEK293 cells. Comparison of total myc-tagged GFPT1 amounts in HEK293 
cells transfected with either wild-type or mutant GFPT1 constructs showed a reduction of the 
GFPT1 expression to 83 % for p.Arg111Cys, 58 % for p.Asp43Val and 73 % for p.Met492Thr 
compared to the wild-type GFPT1 amount (Figure 15 and 16). The mutants p.Thr15Ala, 
p.Asp348Thr, p.Arg434His and p.Ile121Thr had no effect on protein expression (Figure 15 and 
16). HEK293 cells transfected only with GFP showed no expression of myc-tagged GFPT1 (Figure 
15). The actin-antibody visualized equal protein loading (Figure 15). 
 
3.1.2 Subcellular localization of mutant GFPT1 species 
Glutaminase and isomerase activities have been attributed to GFPT1 but little is known about the 
regulation and subcellular localization of GFPT1. Mutations that alter protein folding could result 
in abnormal subcellular localization of the mutant protein. To characterize the subcellular 
localization pattern of wild-type and mutant GFPT1-L, SW13 cells were transfected with either 
wild-type or mutant Myc-tagged GFPT1 constructs and investigated by indirect 
immunofluorescence microscopy with appropriate antibodies.  
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Figure 17: Subcellular localization of GFPT1 mutants. 
SW13 cells were transfected with either wild-type or mutant Myc-tagged GFPT1 constructs. Cells were stained 
with a mouse monoclonal antibody that recognizes the Myc-tag, followed by an anti-mouse IgG secondary 
antibody conjugated to a green fluorescent dye (Alexa Fluor 488).  
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Immunofluorescence microscopy using an antibody that recognizes the Myc-tag of the transiently 
expressed GFPT1 species reveals that all mutants show a diffuse cytoplasmic staining pattern 
similar to wild-type GFPT1 (Figure 17). GFPT1 was not detected in the nucleus. At high 
expression levels, some GFPT1 constructs, including wild-type, tend to form aggregates (Figure 
17). This finding is most likely non-specific and rather results from the high non-physiological 
expression level. 
 
3.1.3 Enzyme activity of GFPT1 mutants 
The activity of the rate-limiting enzyme of the hexosamine biosynthetic pathway (HBP), 
Glucosamine-fructose-6-phosphate aminotransferase 1 (GFPT1) was measured in vitro by the 
glutamate dehydrogenase (GDH) method in transiently transfected cells. HEK293 cells were 
transfected with either wild-type or mutant GFPT1 constructs. For this series experiments I 
decided to use untagged GFPT1 as myc-tagged GFPT1 did not exhibit enzyme activity. The aim of 
these studies was to investigate whether GFPT1 missense mutations, observed in LG-CMS 
patients may cause NMJ and muscle pathology through altered enzyme activity.  
 
 
 
Figure 18: Determination of the GFPT activity 
The enzyme activity is measured by quantification of glutamate using glutamate dehydrogenase (GDH) as 
coupling enzyme. Reduction of the 3-acetylpyridine analogue of NAD+ (acetylpyridine adenine dinucleotide, 
APAD) by GDH can be followed spectrometrically by the measurement of the absorbance at 370 nm. 
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Figure 19: Analysis of the enzymatic activity of GFPT1 mutants 
HEK293 cells were transfected with either wild-type or mutant untagged GFPT1 constructs. GFPT1 enzyme 
activity was measured in cell lysates with the glutamate dehydrogenase method 48 h after transfection. The 
enzymatic activity of each mutant was normalized to GFPT1 protein amounts determined by Western blot analysis 
of cell lysates. Three independent transfection experiments were performed for each mutant and lysates were 
measured in triplicates. Error bars indicate + SD; significant differences from wild-type **P < 0.01; ***P < 
0.001. n.s., not significant.  
 
Heterologous expression of GFPT1 mutants and analysis of the GFPT1 enzyme activity using the 
the GDH method revealed that the mutations p.Thr15Ala (relative activity of about 71 %), 
p.Asp43Val (relative activity of about 58 %) and p.Asp348Tyr (relative activity of about 82 %) 
had small effects on enzymatic activity. Furthermore, the mutants p.Arg111Cys (relative activity 
of about 97 %) and p.Arg434His (relative activity of about 88 %) had no statistically measurable 
effect on enzymatic activity. Mock transfected HEK293 cells showed only a low GFPT1 enzyme 
activity (relative activity of about 6 %). This finding correlates with the result that HEK293 cells 
express only low protein levels of endogenous GFPT1 compared to cells transfected with GFPT1 
constructs.  
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4 Investigation of the 3’-UTR mutation c.*22C>A 
 
The c.*22C>A mutation in the 3’-UTR of the GFPT1 gene was identified heterozygously in four 
independent families from Spain and Germany (LGM5, 9, 12 and patient 4). It was determined 
that the 3’-UTR mutation c.*22C>A is associated with reduced amounts of GFPT1 protein levels 
in myoblasts, myotubes and muscle tissue obtained from three patients (Figure 13) [65]. 
Sequence analysis of the GFPT1 cDNA of these patients excluded major degradation of the 
c.*22A mRNA species relative to the mRNA amount transcribed from the 2nd allele [65]. However, 
no absolute quantification of GFPT1 mRNA levels was performed in these patients. Because this 
variant does not alter the GFPT1 open reading frame, its pathogenic relevance has not yet been 
extablished. Therefore, experiments were designed to characterize the pathomechanism related 
to c.*22C>A.  
 
 
 
 
Figure 20: 3'-UTR mutation c.*22C>A in the GFPT1 gene. 
The mutation in the 3’-UTR of GFPT1 has been identified in 3 independent families (LGM5, 9 and 12) by linkage 
and homozygosity data (Table 15). After the identification of GFPT1 mutations in LG-CMS patients, this mutation 
has been identified in one further patient (Patient 4, Table 17). The compound heterozygous state of the 
mutation has been confirmed [65]. The mutation is located after the open reading frame (ORF) of GFPT1, 22 bp 
downstream of the translation termination codon (TGA) in the 3’-UTR (red arrow indicates the position of the 
mutation). Dark shading indicates coding regions, green and red shading indicates untranslated regions and 
introns are shown as a line. Large introns are not shown completely (double vertical lines).    
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4.1 Relative quantification of GFPT1 mRNA in myoblast and 
muscle lysates 
 
As a first experiment, GFPT1 mRNA levels were quantified in total RNA derived from the myoblast 
and muscle samples of GFPT1 patients carrying the c.*22C>A mutation and a missense change 
on the 2nd allele, and control individuals. The mRNA levels were analysed and quantified by real-
time qRT-PCR.  
 
 
 
Figure 21: GFPT1 relative expression in myoblasts. 
Relative expression of GFPT1 mRNA in myoblast samples obtained from GFPT1 patient (LGM5.3, 5.5 and 9.3) 
compound heterozygous for c.*22C>A and two healthy control individuals (ctr1 and 2). LGM 5.3 and 5.5 are 
compound heterozygous for c.*22C>A and c.1475T>C (p.Met492Thr); LGM9.3 is compound heterozygous for 
c.*22C>A and c.595G>T (p.Val199Phe). Transcript levels were analysed by qRT-PCR and normalized to histone 
hH4. Error bars indicate + SD; significant differences from control 2 (ctr2) *P < 0.05. n.s., not significant. 
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Figure 22: GFPT1 relative expression in muscle. 
Relative expression of GFPT1 mRNA in muscle biopsy samples obtained from a control individual (wt) and a 
GFPT1 patient (patient 4 of this study), compound heterozygous for c.*22C>A and c.1649C>T (p.A550V). 
Transcript levels were analysed by qRT-PCR and normalized to histone hH4. Error bars indicate + SD; n.s., not 
significant. 
 
 
The quantification of the GFPT1 mRNA levels in total RNA derived from myoblasts of patients 
with the c.*22C>A mutation (LGM5.3, 5.5 and 9.3) by real-time qRT-PCR revealed no gross 
changes in the GFPT1 mRNA level compared to control individuals (ctr 1 and ctr 2) (Figure 21). 
Consistently, the real-time qRT-PCR analysis revealed almost identical GFPT1 relative expression 
in skeletal muscle of a GFPT1 patient (1.02), compound heterozygous for c.*22C>A and 
c.1649C>T (p.A550V), and a control individual (ctr) (1.0) (Figure 22). A significant difference 
between the GFPT1 transcript level of patients (LGM5.3 and LGM5.5) compared to a healthy 
control individual (ctr2) was observed only in myoblast cells from one family (LGM5) (Figure 21). 
There was no significant difference in all other analysed patients (Figure 21 and figure 22). This 
result indicates that the reduced amounts of GFPT1 protein levels in muscle and myoblast lysates 
(Figure 13) of GFPT1 patients [65] resulted from repression of translation rather than altered 
mRNA stability. 
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4.2 Expression analysis of the 3’-UTR mutation c.*22C>A 
 
To confirm the association of the 3’-UTR mutation c.*22C>A with lower amounts of GFPT1 
protein directly in a controlled experiment, C2C12 myoblasts were transfected with either wild-
type or mutant GFPT1 constructs. The constructs used here contained the GFPT1-L coding region 
and about 100 bp of its endogenous 3’-UTR downstream of the TGA stop codon in wild-type or 
mutant c.*22C>A state.   
 
 
 
 
Figure 23: Western Blot of GFPT1 in C2C12 cells transiently transfected with GFPT1-3’-UTR wt or 
mutant (c.*22C>A) constructs. 
The cells were co-transfected with a GFP expression vector for transfection efficiency control. The intensities of 
the bands were measured and GFPT1 expression was normalized to the GFP and α-tubulin levels. Each bar 
represents the average GFPT1 protein levels observed in n=3 independent experiments in C2C12 cells. Data are 
shown relative to the wt GFPT1 level.  
 
Western Blot analysis of C2C12 cells transfected with either GFPT1 wild-type or mutant 
constructs revealed that the 3’-UTR mutation leads to a significant decrease in GFPT1 expression 
levels compared to wild-type (Figure 23 A, top) confirming the association of GFPT1 c.*22C>A 
with reduced GFPT1 protein levels in a controlled assay. Co-transfection of a GFP expression 
vector shows equal transfection efficiency for both constructs (Figure 23 A, bottom). The 
experiment revealed a reduction in the expression of the mutated construct to 36 % (Figure 23 
B) compared to wild-type (wt). This result confirms the association of GFPT1 c.*22C>A with 
reduced GFPT1 protein levels.  
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4.3 The mutation c.*22C>A creates a miR-600 and miR-206* 
binding site in the GFPT1 3’-UTR 
 
It has been shown that endogenous GFPT1 protein amounts are reduced in myoblasts, myotubes 
and muscle tissue samples of patients with the c.*22C>A mutation [65] and the findings from 
the expression analysis of transfected cells in this study support this observation (Figure 23). On 
the other hand, GFPT1 mRNA levels seemed largely unchanged in a muscle biopsy and myoblast 
samples of patients with the 3’-UTR variant. Thus the pathogenic effect of the 3’-UTR mutation 
may be mediated through downregulation of GFPT1 protein translation. One mechanism of 
expression regulation is miRNA binding to its target mRNA. The binding results in translational 
repression through either the degradation of the mRNA or its translational inhibition. Considering 
the possibility that the 3’-UTR variant may have an effect on the regulation of GFPT1 expression, 
in silico analyses were undertaken and revealed two potential miRNA binding sites.  
 
 
 
Figure 24: Schematic representation of the sequence alignment of the hsa-miR-600 and the miR-
206* with wild-type (wt) and the variant (c.*22C>A) GFPT1 mRNA. 
Bioinformatics tools on http://bioinfo.uni-plovdiv.bg/microinspector/ and http://www.mirbase.org/search.shtml 
revealed that the 3’-UTR mutation c.*22C>A may result in a gain of a putative binding site in the 3’-UTR for both 
the miR-600 and miR-206* miRNA. (A) miR-600 alignment [MIMAT0003268]. The mutation creates a 7mer-A1 
site which is highlighted in grey. The GFPT1 3’-UTR c.*22C>A mutation is shown in red. (B) miR-206* 
[MIMAT0006994] alignment shows imperfect seed pairing, but compensatory pairing in the 3’-region of the 
miRNA. The GFPT1 3’-UTR c.*22C>A mutation is shown in red. Cycles indicate wobble base pairing (G:U), while 
lines indicate Watson-Crick base pairing. The seed region is highlighted in grey. 
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In silico analysis revealed that the c.*22C>A variant results in a sequence matching the seed of 
mature hsa-miR-600 (5’CUUACA3’; Figure 24 A). The predicted hsa-miR-600 site in the variant 
GFPT1 3’-UTR is a 7mer-A1 seed match type, which comprises the exact seed match (position 2-
7 of the mature miRNA) supplemented by an A across from miRNA nucleotide 1 (Figure 24 A). 
The mutation c.*22C>A changes the 3’-UTR sequence from 5’UGUACG3’ (wild-type) to 
5’UGUAAG3’ (mutant c.*22C>A) generating a perfect match to the seed of hsa-miR-600 (Figure 
24 A). 
In addition, the GFPT1 variant also leads to the gain of a putative binding site on its 3’-UTR for 
miR-206*. There is no perfect seed matching but there seems to be a compensatory base pairing 
site in the 3’-region of the miR-206*. The c.*22C>A variant lies within the compensatory site and 
the C>A change results in an additional Watson-Crick base pairing (A:U) (Figure 24 B).  
 
4.3.1 Hsa-miR-600 controls the expression of mutant GFPT1 
In order to test the interaction between mutant GFPT1 and miR-600, co-expression studies were 
performed. HEK293 cells were transfected with GFPT1-3’-UTR wt or mutant (c.*22C>A) 
constructs together with the empty pENTR vector or with the miR-600 expression vector pEF1-
miR-600. The GFPT1 protein amounts were investigated 24 or 48 h after transfection by Western 
blot analysis with appropriate antibodies. To investigate potential downstream effects of altered 
GFPT1 levels, I made use of the RL2 antibody which recognises single O-GlcNAc modifucations of 
proteins [123].  
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Figure 25: Western Blot of GFPT1 and O-GlcNAcylation in HEK293 cells transfected with GFPT1-3’-
UTR wt or mutant (c.*22C>A) constructs. 
The cells were co-transfected with either an empty pENTR vector or a pENTR vector expressing the hsa-miR-600. 
Cells were lysed either 24 or 48 h after transfection. The RL2 antibody detects single N-acetylglucosamine 
modifications at serine or threonine residues [123].   
 
The microRNA miR-600 downregulates the expression of mutant GFPT1. Co-transfection of the 
mutant GFPT1-3’-UTR construct with the miR-600 expression vector pEF1-miR-600 led to a 
reduction of the mutant GFPT1 protein amount compared with the amount of mutant GFPT1 co-
trasfected with the empty pENTR vector (Figure 25) after 24 hours. Due to the limited lifetime of 
the small microRNA miR-600, no reduction of the mutant GFPT1 protein was observed 48 hours 
after transfection. In contrast, the protein amount of wild-type GFPT1 co-transfected with the 
miR-600 expression vector was almost the same as co-transfected with the empty vector after 24 
and 48 hours. Furthermore, immunoblotting of lysates from co-transfected HEK293 cells with the 
RL2 antibody, which selectively detects O-linked N-acetylglucosamine (O-GlcNAc) residues on 
numerous proteins [123], revealed markedly decreased band intensities when the mutant 
Marina Dusl  RESULTS 
 
84 
 
construct was co-transfected with the miR-600 expression vector. In contrast, compared to the 
band intensities detected with the RL2 antibody after 24 hours (+/- miR-600), the intensities 
were markedly increased after 48 hours when co-transfecting the wild-type construct together 
with the miR-600 expression vector. This result correlates with the higher expression level of 
GFPT1 after 48 hours compared to the expression level after 24 hours (+/- miR-600) and 
confirms that the expression of the miR-600 has no influence on the expression of wild-type 
GFPT1 (Figure 25). 
 
4.3.2 Expression profile of the microRNAs miR-206* and miR-600 
As the expression of microRNAs is spatially and temporally controlled, the expression profile of 
miR-206* and miR-600 was investigated. It is known that miR-206 is highly expressed in human 
skeletal muscle and may play a potential role in myogenesis [124-128]. Its expression is robustly 
induced during the myoblast-myotube transition in primary human myoblasts [129]. However, 
there is no information on the abundance of its star-form miR-206*. Concerning miR-600, there 
is only one publication on the expression of this microRNA in human colorectal cells [130]. 
The microRNAs were quantified by a two-step real-time PCR using the miScript-Reverse 
Transcription kit and the miRNA-SYBR Green PCR Kit. The first step includes polyandenylation 
and reverse transcription of total RNA, followed by real-time PCR. In addition to dissociation 
curve analysis, the PCR products were run on an agarose gel to verify specificity of the 
amplification. 
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Figure 26: Expression profile of miR-206* (A) and miR-600 (B). 
qRT-PCR to detect miR-206* and miR-600 was performed on cDNA samples from muscle biopsies and myoblasts 
(MB) obtained from  GFPT1 patients (pat), heterozygous for c.*22C>A, compared to control (ctr) muscle, human 
myoblasts (MB), myotubes (MT) and C2C12 cells. MB pat (LGM9): compound heterozygous for c.*22C>A and 
c.595G>T (p.V199F); muscle pat (patient 4 of this study): compound heterozygous for c.*22C>A and c.1649C>T 
(p.A550V). PCR products were run on an agarose gel to verify specificity. U6 snRNA was used as normalization 
control. (C) Relative expression of the microRNA miR-600 and miR-206* in muscle samples of the patient. 
miRNAs were detected by qRT-PCR and normalized to U6 snRNA. miScript PCR control primers for U6 snRNA 
show relatively constant expression levels across the different samples. 
 
To determine the abundance of miR-206*, real-time qRT-PCR was performed on RNA samples 
from muscle, myoblasts and myotubes (Figure 26 A). The expression of the miRNAs was 
analysed in samples obtained from GFPT1 patients compound heterozygous for the mutation 
c.*22C>A and control individuals. The miR-206* is robustly expressed in muscle and myoblast 
cells of GFPT1 patients and controls. The star-form is also abundant in C2C12 cells and myotubes 
of controls. Gel electrophoresis analysis of the amplicon confirms the presence of a single specific 
fragment of the expected size (~ 90 base pairs).  
The microRNA miR-600 is also detectable in RNA samples obtained from human muscle biopsies 
and myoblast samples of GFPT1 patients as well as in C2C12 cells (Figure 26 B). Gel 
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electrophoresis analysis of the PCR products revealed the presence of a single specific fragment 
of the expected size (~ 90 base pairs) in the patient muscle biopsy sample, but there was a 
second, non-specific fragment of approximately 110 base pairs in human myoblasts and C2C12 
cells (Figure 26 B).  
The relative quantification by real-time qRT-PCR of the miRNA samples derived from human 
muscle samples showed that the miR-206* is more abundant (~2x) in patients’ muscle biopsies 
than the miR-600 (Figure 26 C). 
 
4.3.3 Relative expression profile of the microRNAs miR-206 and 206* 
 
 
 
Figure 27: Expression profile of hsa-miR-206 and miR-206*. 
Detection of miRNAs hsa-miR-206 and miR-206* in muscle, myoblasts and myotubes. The miRNAs were isolated 
with the miRNeasy Kit. RT-PCR was performed using the miScript SYBR Green PCR Kit containing QuantiTec 
Primer sets specific for hsa-miR-206, oan-miR-206* or U6 snRNA. U6 snRNA was used as an internal control. 
qRT-PCR was performed on cDNA samples from muscle and myoblasts (MB) obtained from two different GFPT1  
patients (pat), heterozygous for c.*22C>A, compared to control (ctr) muscle, human myoblasts (MB), myotubes 
(MT) and C2C12 cells. (A) The PCR products were confirmed by 4 % agarose gel electrophoresis. (B) Relative 
expression of the microRNAs miR-206 and miR-206* in myoblast (MB) and myotube (MT) samples of controls 
(ctr). (C) Relative expression of the microRNAs miR-206 and miR-206* in myoblast (MB) samples of a GFPT1 
patient (pat) and two controls (ctr). MB pat: compound heterozygous for c.*22C>A and c.595G>T (p.V199F); 
muscle pat: compound heterozygous for c.*22C>A and c.1649C>T (p.A550V).  
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The miR-206 is known to be robustly induced during the myoblast-myotube transition in primary 
human myoblasts [129, 131]. Consistent with this, qRT-PCR analysis of myoblast and myotube 
samples of a healthy control individual showed that the miR-206 is more abundant in myotubes 
than in myoblasts (Figure 27 A and B). Furthermore, the qRT-PCR assay revealed also that star-
form miR-206* is detectable in myoblasts and is further upregulated upon differentiation (Figure 
27 A and B) like known from the miR-206. 
In addition, relative quantification showed that both miR-206 and miR-206* are more abundant 
in myoblast (MB) samples of a GFPT1 patient (pat) than in two controls (ctr) (Figure  27 C).  
Gel electrophoresis of qRT-PCR products (miR-206 and miR-206*) confirmed the presence of a 
specific fragment (~ 90 base pairs). No non-specific fragments were observed. miScript PCR 
control primers for U6 snRNA show relatively constant expression levels across the different 
samples (Figure  27 A). 
 
4.3.4 Reporter assay testing the interaction between putative regulatory 
miRNAs and mutant GFPT1 
In order to test the hypothesis that the GFPT1 3’-UTR mutation c.*22C>A leads to the gain of a 
miRNA binding site, a reporter gene assay was performed. This assay offers the opportunity to 
test the interaction between the mutant 3’-UTR and microRNAs directly. 
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Figure 28: Schematic representation of the Renilla luciferase (Ren-luc) expression vectors and the 
GFPT1 gene. 
Four tandem repeats (4xA or 4xC) or a single unit (1xA or 1xC) of an 80 bp sequence around GFPT1 c.*22 with C 
(wild-type; wt) or A (c.*22C>A; mutant; mut) were subcloned downstream of the Ren-luc gene. * indicates the 
position of the mutation (c.*22C>A); (pA): poly(A) signal  
 
Either four tandem repeats (to increase the effect) or a single unit of an 80 bp sequence around 
GFPT1 c.*22 with C (wt) or A (c.*22C>A; mut) were subcloned downstream of the luciferase 
gene (Figure 28). RNAfold programme was used to avoid the occurrence of secondary RNA 
structures that might interfere with miRNA binding due to secondary structures of the tandem 
repeats.  
 
4.3.4.1 Reporter assay for testing the interaction between putative regulatory 
miRNA miR-600 and mutant GFPT1 
Reporter gene assays are widely used to study gene expression. The dual-luciferase reporter 
assay enables the simultaneous expression of the Renilla and firefly luciferase. While the partial 
GFPT1 3’-UTR (wt and c.*22C>A) was cloned downstream of the Renilla luciferase gene (Figure  
24), an empty firefly luciferase reporter vector was used as control. After cell lysis, the firefly 
luminescent signal is measured first by adding the appropriate reagent. After quantifying this 
luminescence, the reaction is quenched, and the Renilla luciferase reaction is initiated. In order to 
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correct for vector-dependent unspecific effects relative reporter activity was obtained by 
normalization to firefly luciferase activity. MiR-mimics are double-stranded miRNA-like RNA 
fragments. Once introduced into the cell, this small RNA fragment mimics an endogenous miRNA, 
binds to its target gene and leads to posttranscriptonal repression of the gene [132, 133].  
Reporter gene vectors and the appropriate miR-mimic (or control) were transiently transfected 
into COS-7 cells and the Renilla luciferase relative to the firefly luciferase activity was measured. 
Since COS-7 cells do not express miR-206 endogenously, miR-206 levels can be easily titrated by 
transfection with a cognate miRNA expression vector, and this cell line was chosen for reporter 
assay experiments [134]. Likewise, the microRNA miR-600 is not abundant in COS cells either.  
 
 
 
Figure 29: Renilla-to-firefly luminescence ratios  
Renilla-to-firefly luminescence ratios observed when co-transfecting COS-7 cells with the luciferase reporter pRL-
4xA (mut) with either 0, 10, 50 or 100 nM miR-600. Error bars indicate +SD obtained from three replicates.  
 
In order to find the right miR-600 concentration for further experiments, dose-response 
experiments of the pRL-4xA (mut) construct and the miR-600 (either 0, 10, 50 or 100 nM) were 
performed. The highest effect (reduction of the signal to ~ 50 %) was achieved with 100 nM 
miR-600 (Figure 29).   
   
Marina Dusl  RESULTS 
 
90 
 
 
 
Figure 30: Renilla-to-firefly luminescene ratios 
Renilla-to-firefly luminescence ratios observed when co-transfecting COS-7 cells with the indicated luciferase 
reporter (pRL, pRL4xC or pRL4xA) and either 100 nM control miRNA, 100 nM miR-600 (A) or 300 nM miR-600 
inhibitor (B). Error bars indicate +SD obtained from three replicates. *: P < 0.05; ***: P < 0.001; **: P < 0.01. 
 
In agreement with the prediction that miRNA miR-600 downregulates the expression of  GFPT1 
c.22*C>A, co-transfection of the reporter constructs (pRL, pRL4xC or pRL4xA) with the miR-600 
led to a highly significant reduction of the pRL-4xA (mut) signal to ~ 66 % of the signal obtained 
with pRL-4xC (wt) or the unmodified pRL (Figure 30 A). On the other hand, when co-transfecting 
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the same reporter constructs with a control miRNA, there was no significant difference between 
luminescence obtained with pRL-4xC, pRL-4xA or unmodified pRL. The pRL-4xA (mut) signal co-
transfected with the miR-600 was significantly decreased to ~ 57 % of the signal obtained with 
the pRL-4xA (mut) construct co-transfected with the control miRNA. As opposed to this, co-
transfection of miR-600 had no significant effect on the pRL-4xC (wt) signal compared to control 
miRNA.  
Addition of a miR-600 inhibitor to cells co-transfected with the pRL-4xA (mut) construct and miR-
600 restored the signal to the level obtained with the pRL-4xA (mut) construct co-transfected 
with the control miRNA (Figure 30 B).  
These results indicate that miR-600 specifically repressed luciferase activity of mutant constructs 
containing the c.*22C>A but had no effect on the wild-type sequence. Moreover, derepression 
was obtained with an inhibitor against miR-600.   
 
The experiments were repeated with luciferase vectors into which a single transcript unit of an 
80bp sequence around GFPT1 c.*22 with either C (wt) or A (c.*22C>A; mut) was subcloned, 
creating constructs pRL-1xC (wt) and pRL-1xA (mut) respectively (Figure 28).  
 
 
Figure 31: Renilla-to-firely luminescence ratios  
Renilla-to-firefly luminescence ratios observed when co-transfecting COS-7 cells with the indicated luciferase 
reporter (pRL, pRL1xC or pRL1xA) and either 100 nM control miRNA or miR-600. Error bars indicate +SD 
obtained from three replicates. *: P < 0.05. 
Marina Dusl  RESULTS 
 
92 
 
The signal obtained from pRL-1xC (wild-type) did not change when COS7 cells were co-
transfected with control miRNA and miR-600, whereas a significant reduction of the pRL-1xA 
(mutant) signal was obtained in cells co-transfected with miR-600 compared to cells 
cotransfected with control miRNA (decrease to ~ 70 %) (Figure 31). However, stronger effects 
were achieved with the tandem constructs (4xC or 4xA).   
 
4.3.4.2 Reporter assay for testing the interaction between putative regulatory 
miRNA miR-206* and mutant GFPT1 
Similar to the experimental setup for the miR-600, the dose-response between the pRL-1xA 
(mut) reporter construct and miR-206* was determined for further experiments. The reporter 
gene vector pRL-1xA (mut) and the miR-206* mimic (or control) were transiently transfected into 
COS-7 cells and the Renilla luciferase relative to the Firefly luciferase activity was measured. 
 
 
 
Figure 32: Renilla-to-firefly luminescence ratios 
Renilla-to-firefly luminescence ratios observed when co-transfecting COS-7 cells with the luciferase reporter pRL-
1xA (mut) and 100 nM miR-206*. Error bars indicate +SD obtained from three replicates.  
 
In agreement with the prediction that miRNA miR-206* downregulates the expression of mutant 
GFPT1, co-transfection of the reporter construct pRL1xA (mut) with 100 nM miR-206* led to a 
highly significant reduction of the pRL-1xA (mut) signal to ~ 58 % of the signal obtained with 
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pRL-1xA co-transfected with the control miRNA (Figure 32). This miR-206* concentration was 
kept for the following experiments.  
 
 
 
 
Figure 33: Renilla-to-firefly luminescence ratios 
Renilla-to-firefly luminescence ratios observed when co-transfecting COS-7 cells with the indicated luciferase 
reporter (pRL, pRL1xC or pRL1xA) and either 100 nM control miRNA or miR-206* oligonucleotide. Error bars 
indicate +SD obtained from three replicates. *: P < 0.05; ***: P < 0.001; **: P < 0.01. 
 
When co-transfecting the reporter constructs (pRL, pRL1xC or pRL1xA) with miR-206*, a 
significant reduction of pRL-1xA (mut) signal to ~66 % of the signal obtained with pRL-1xC (wt) 
was observed (Figure 33). On the other hand, when the same reporter constructs were co-
transfected with a control miRNA, no significant difference between luminescence was obtained 
for pRL-1xC or pRL-1xA. Co-transfection of pRL1xA (mut) and miR-206* yielded ~61 % of the 
signal obtained with the pRL-1xA (mut) construct co-transfected with the control miRNA. As 
opposed to that, pRL-1xC (wt) showed similar signals when expressed together with miR-206* or 
control miRNA. Altogether, the results indicate that miR-206* repressed luciferase activity only in 
case of mutant constructs containing the c.*22C>A site. 
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H Discussion 
 
1 Identification of mutations in the GFPT1 gene in LG-CMS 
patients  
 
Limb-girdle congenital myasthenic syndrome (LG-CMS) is an autosomal recessively inherited 
subform of CMS and a long-recognized entity in the clinical literature [135]. This type of CMS is 
characterized by prominent proximal muscle weakness. Over the past years it became apparent 
that LG-CMS is a less homogeneous entity than previously thought. At least two subgroups of LG-
CMS patients have now been recognized. Mutations in the DOK7 gene were identified as 
underlying genetic defect in one subgroup of LG-CMS patients who do not show tubular 
aggregates in muscle biopsies and do not benefit from acetylcholinesterase (AChE) inhibitor 
treatment [49, 136-138]. The other subgroup responds well to AChE inhibitors and muscle 
biopsies are characterized by the presence of tubular aggregates. Although the identification of 
the molecular defect is of paramount importance as it has direct impact on the clinical 
management of CMS patients, the genetic basis for AChE inhibitor-responsive LG-CMS with 
tubular aggregates has remained unidentified until now. 
In order to identify the underlying genetic defect, we made use of our collection of LG-CMS 
families and performed genome-wide linkage analysis. The genome scan mapped the LG-CMS 
locus on chromosome 2 (2p12-p15) and sequencing of different genes at this locus in selected 
index patients revealed mutations in the GFPT1 gene. In total, 18 different GFPT1 mutations 
consisting of 13 missense mutations, three frameshift mutations, one nonsense mutation and one 
in the 3’-UTR were found in 13 out of the 16 LG-CMS families included in the initial study that 
lead to the identification of GFPT1 as a new CMS gene (Table 15 and figure 7) [65].  
In addition, GFPT1 mutation screening in 15 isolated CMS patients yielded three additional novel 
GFPT1 missense mutations (p.S213N, p.G354R, p.S191I; Figure 10) in three LG-CMS patients. 
The disease causing effect of these mutations on the GFPT1 protein was predicted by the 
MutationTaster algorithm (http://www.mutationtaster.org) [122]. The mutations are not listed in 
the Exome Variant Server (http://evs.gs.washington.edu/EVS/). The parents of these patients 
carried mutations in the heterozygous state. One further missense change (p.S191I) was 
identified heterozygously in a patient without second mutation. Autosomal dominant inheritance 
was excluded since the healthy father of this patient (patient 3) carried the mutation 
heterozygously, too. This change might still be a polymorphism or the second mutation was not 
detectable by standard exon sequencing of genomic DNA. The analysis of the cDNA reverse 
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transcribed from muscle RNA of this patient (Figure 11) revealed no second mutation. 
Sequencing of the entire UTRs of the GFPT1 gene might be necessary to further clarify the 
genetic defect of this patient (patient 3).  
 
Up to now, the identified GFPT1 missense or frameshift mutations are spread over the whole 
gene and affect the glutaminase as well as the sugar isomerase domain (Figure 7 and figure 10). 
There seems to be no mutation hot-spot in the GFPT1 gene. In contrast, common mutations are 
well known in other CMS genes. For instance, the overwhelming majority of DOK7 patients 
harbor the common frame-shift mutation c.1124_1127dupTGCC; p.Pro376ProfsX30 in exon 7 on 
at least one allele [19]. Common mutations are also known for the CMS genes CHRNE 
(c.1267delG; exon 12, founder mutation in South-Eastern Europe) [139] and RAPSN 
(p.Asn88Lys; exon 2, founder mutation in patients from Central Europe) [140]. 
 
1.1 Novel pathomechanism in CMS characterized by the defect in 
glycosylation due to GFPT1 mutations  
 
The GFPT1 enzyme is extremely well conserved among species. It catalyses the first and rate-
limiting step of the hexosamine synthesis pathway (Figure 3), transferring an amino group from 
glutamine to fructose-6-phosphate, to produce glucosamine-6-phosphate and glutamate. 
Glucosamine-6-phosphate is subsequently used to synthesise uridine diphospho-N-
acetylglucosamine (UDP-GlcNAc), UDP-N-acetylgalactosamine, and cytidine monophospho (CMP)-
sialic acid. These molecules are essential components for the glycosylation of proteins and lipids.  
The enzyme GFPT1 and the HBP are known to be implicated in signaling pathways that may 
become deregulated in diseases of the immune system, cancer, diabetes mellitus, cardiovascular 
disease and neurodegenerative diseases [97, 141]. However, GFPT1 mutations had not 
previously been linked to a human disease and implicate a novel pathomechanism (impaired 
glycosylation) for NMJ disorders. Many key proteins of the NMJ are glycosylated [142] including 
AChR subunits, agrin, MuSK, dystroglycan and integrins. Furthermore, several proteins are known 
to be O-GlcNAc-modified in skeletal muscle including contractile proteins such as actin and 
myosin [143], but also glycolytic enzymes, signal transduction proteins and heat-shock proteins 
[144, 145]. In addition, it is assumed that O-GlcNAc variations could control the muscle protein 
homeostasis and could be implicated in the regulation of muscular atrophy [145].  
Interestingly, a missense mutation in the epsilon subunit of the AChR (p.S143L) is located at one 
of the N-glycosylation sites of this protein and causes CMS by preventing AChR expression at the 
cell surface [146]. Besides, the treatment with an inhibitor of protein glycosylation (tunicamycin) 
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as well as in vitro mutations of AChR subunits that prevent glycosylation reduce the cell surface 
expression of AChR either through a failure in efficient assembly of the pentameric AChR or 
through a decrease of metabolic stability [147]. Indicating that aberrant glycosylation of NMJ 
proteins may lead to loss of expression of the respective protein.   
In skeletal and heart muscle, the predominant splice variant is called GFPT1-L or muscle-specific 
variant. These variant has a 54 bp insertion compared to the shorter ubiquitous splice variant 
GFPT1 [73]. 
As glycosylation is essential for cell survival, complete loss of the GFPT1 protein would likely be 
detrimental for organs like kidney, pancreas and liver where GFPT1 is the only or predominant 
isoform [73]. For that reason, GFPT1 germline mutations causing LG-CMS are expected to create 
hypomorphic alleles with a residual function of the enzyme rather than resulting in complete loss-
of-function. This is in line with the observation that none of the GFPT1 patients (LGM1-16 and 
patient 1-4) carried two null mutations in the exons 1-19 (constitutive exons) of the GFPT1 gene 
(Figure 7 and Figure 10). The homozygous p.Trp240X mutation (likely to result in severely 
truncated GFPT1 or no protein at all) occurs in an alternative exon (exon 8A; Figure 7), 
exclusively incorporated in the predominant GFPT1 species in striated muscle (GFPT1-L), and is 
therefore supposed to lead to decreased GFPT1 levels only in heart and skeletal muscle. 
Something similar is known from CMS patients with mutations in the subunits of the AChR which 
account for about 50 % of CMS in a cohort of 295 patients [15], indicating that there is a 
correlation between the expression profile of a gene and the severity of mutations in this gene. 
Patients harboring null mutations in both alleles of the α-, β-, or δ-AChR subunits are rare and 
they have a very severe course of the disease with high fatality [15, 17]. In contrast, patients 
harboring null mutations in both alleles of the AChR ε-subunit generally have only mild 
symptoms. An explanation might be that the expression of the fetal γ-subunit partially 
compensates for the absence of the ε-subunit and rescues the phenotype [37, 148].   
 
1.2 Genotype-phenotype correlations 
 
GFPT1 mutations are associated with a myasthenic syndrome (which can be confirmed by 
repetitive nerve stimulation (RNS)), limb-girdle weakness, response to AChE-inhibitor therapy and 
tubular aggregates (TAs) in muscle biopsies whereas facial weakness, respiratory difficulties, 
ophthalmoparesis and ptosis are usually absent. TAs in muscle biopsies are not an obligatory 
finding in patients with GFPT1 mutations. The present data also confirm earlier observations, that 
the genetic causes of TAs are heterogeneous: Sequencing of the three patients with LG-CMS and 
tubular aggregates (families LGM4, 15 and 16 described in [149]; Figure 6) did not reveal GFPT1 
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mutations. Moreover, four patients without a myasthenic syndrome but with TAs in muscle 
biopsies did not reveal GFPT1 mutations either. This finding is in line with the fact that the 
functional significance of TAs in skeletal muscle has not yet been fully understood. It is unknown 
whether they represent pathological structures or compensatory reactions to diverse pathogenic 
events such as periodic paralysis, dyskalaemia, intoxication, inflammatory myopathies, cramps 
and myalgias, myotonia congenita, familial myopathies, and several other myopathies of 
uncertain etiology [68, 69]. TAs were initially thought to originate from mitochondria. However, 
work of several groups has shown that TAs rather arise from the sarcoplasmatic reticulum [70]. 
Patients with TAs but without GFPT1 mutations may still carry cryptic mutations in GFPT1 which 
are not detectable by standard exon sequencing of genomic DNA, or they may carry mutations in 
other, yet unknown genes. Genes encoding enzymes of the HBP pathway downstream of GFPT1 
might be novel candidates for GFPT1-negative LG-CMS patients (LGM4, 15 and 16) or cases with 
TA myopathy.  
 
 
 
Figure 34: Synthesis pathways for the formation of UDP-sugars 
Potential candidate genes for CMS are in red. The figure was adapted and modified from [85, 150].  
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GFPT1 is the key and rate-limiting enzyme for UDP-GlcNAc biosynthesis, the end product of 
hexosamine biosynthesis pathway. This pathway involves other enzymes which might be 
potential candidate genes for CMS. The genes coding for the HBP enzymes Glucosamine-6-
phosphate N-acetyltransferase 1 (GNA1, location of the gene: 14q22.1), phosphoglucomutase 3 
(PGM3, location of the gene: 6q14.1-q15), UDP-N-acteylglucosamine pyrophosphorylase 1 (UAP1, 
location of the gene: 1q23.3) and O-linked GlcNAc transferase (OGT, location of the gene: Xq13) 
might be putative novel CMS candidates (Figure 34).   
On the other hand, potential candidate genes might emerge from a second synthesis pathway for 
formation of UDP-sugars which are also needed for the synthesis of proteoglycans. The end 
product of this pathway is UDP-xylose (UDP-Xyl) which is a sugar donor for the synthesis of 
proteoglycans in mammals [151, 152]. Candidates might be genes coding for enzymes like UDP-
glucose pyrophosphorylase 2 (UGP2, location of the gene: 2p14-p13), UDP-glucose 6-
dehydrogenase (UGDH, location of the gene: 4p15.1) and UDP-glucuronate decarboxylase 1 
(UXS1, location of the gene: 2q12.2).  
 
2 Effects of GFPT1 missense mutations on different protein 
features 
2.1 Mutant GFPT1 expression and localization 
 
Analysis of GFPT1 expression in cultured primary myoblasts and in a muscle biopsy, from GFPT1 
patients revealed reduced GFPT1 protein levels compared to controls (Figure 13) [65]. To study 
the effect of the mutations at the protein level in a controlled experiment, plasmid constructs 
were generated to express wild-type and mutant myc-tagged GFPT1-L (muscle-specific variant) 
protein (p.Arg111Cys, p.Asp43Val, p.Met492Thr, p.Thr15Ala, p.Asp348Thr, p.Arg434His and 
p.Ile121Thr) in HEK293 cells. Immunoblot analysis was performed of the myc-tagged GFPT1-L 
protein. HEK293 cells also express endogeneous GFPT1 but its effect was negligible due to the 
overexpression of transfected GFPT1 and use of an anti-myc antibody which only detects GFPT1 
derived from the transfected constructs. Comparison of total GFPT1 amounts in HEK293 cells 
transfected with either wild-type or mutant GFPT1 constructs showed a reduction of GFPT1 
expression to 83 % of p.Arg111Cys, 58 % of p.Asp43Val and 73 % of p.Met492Thr compared to 
the wild-type GFPT1 amount (Figure 15 and 16). The mutants p.Thr15Ala, p.Asp348Thr, 
p.Arg434His and p.Ile121Thr had no effect on protein expression (Figure 15 and16). In contrast 
to the analysis of the GFPT1 expression in LG-CMS patients, the in vitro transfection studies 
(Figure 15 and 16) revealed only a small effect of the missense mutations p.Arg111Cys, 
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p.Asp43Val and p.Met492Thr on protein expression. Compared to the wild-type, the protein levels 
of the mutants were not reduced below 50 %. One explanation might be that for transfection 
studies, the human cytomegalovirus immediate-early gene (CMV) promoter was used instead of 
the endogenous eukaryotic GFPT1 promoter. The CMV promoter induces high-level expression in 
a variety of mammalian cell lines and is probably the most widely used promoter for mammalian 
expression [153]. The artificial high-level expression of the GFPT1 mutants might be the reason 
for the small effect of the missense mutations on the GFPT1 protein levels observed by the 
transfection studies. The use of a promoter region derived from the human skeletal α-actin (HSA) 
gene which is specifically expressed in striated muscles, heart and skeletal muscle and which 
allows low-level expression [154, 155] might overcome this artificial situation.  
The subcellular localization of mutant GFPT1 species (p.Thr15Ala, p.Asp43Val, p.Arg111Cys, 
p.Ile121Thr, p.Asp348Tyr, p.Arg434His and p.Met492Thr), transiently expressed in SW13 cells 
was almost identical to that of wild-type GFPT1 (Figure 17). Altogether, reduced expression of 
mutant GFPT1 protein species is a likely molecular pathomechanism although I could not confirm 
these data in in vitro transfection studies.            
 
2.1.1 Reduced GFPT1 amounts result in reduced O-GlcNAc modification 
Two experimental approaches link reduced amounts of functional GFPT1 protein to reduced 
levels of O-GlcNAc modified proteins. Immunoblot analysis of muscle and myoblast lysates of 
GFPT1 patients and controls with the RL2 antibody, which selectively detects O-GlcNAc residues 
on proteins, showed that O-GlcNAcylated proteins were markedly decreased in lysates from the 
patients’ myoblasts and muscle biopsies (Figure 13) [65]. In addition, knockdown of Gfpt1 
expression in C2C12 cells treated with Gfpt1 siRNA also resulted in a reduction of the levels of O-
linked N-acetylglucosamine on proteins (Figure 14). This is in line with earlier observations of 
others: blockage of GFPT using pharmacological and antisense strategies resulted in a decreased 
RL2 signal on intracellular proteins in Rat aortic smooth muscle (RASM) cells [156]. The 
prominent protein band that is differentially O-GlcNAcylated in immunoblots in both experiments 
(Figure 13 and Figure 14) is most likely heat shock protein 70 (Hsp70). Hsp70 has been shown to 
be O-GlcNAcylated in L6 myotubes (a model of skeletal muscle) [157].  
 
Altered protein glycosylation is a new potential pathomechanism underlying defects of NMJ 
transmission in LG-CMS patients. It is likely that GFPT1 deficiency does not only influence O-
GlcNAcylation of intracellular proteins but may also directly affect clustering of the ACh receptor 
(AChR) and the structure of the NMJ. It has been shown that correct glycosylation of agrin and 
MuSK is necessary to induce clustering of AChRs at the NMJ [158-160]. Furthermore, a mutation 
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in the ε-subunit of the AChR (p.S143L) is located at one of its N-glycosylation sites [146]. It could 
be shown that this mutation causes CMS by preventing AChR expression at the cell surface which 
indicates that aberrant glycosylation of NMJ proteins may lead to loss of expression of the 
respective protein and thereby to a neuromuscular disorder.  
Defects in O-GlcNAcylation have also been described in other pathologies, including Alzheimer’s 
disease. Several proteins that have been thought to be involved in this neurodegenerative 
disease (e.g. tau and the β-amyloid precursor protein) are modified by O-GlcNAc and there is 
some evidence that reduced O-GlcNAc levels are associated with the disease [161]. 
 
2.2 Mutant GFPT1 enzyme activity  
 
GFPT1 catalyses the first step in de novo biosynthesis of hexosamines. To analyse the impact of 
mutations on GFPT1 enzymatic activity, the wild-type long isoform GFPT1-L containing a striated 
muscle-specific 18 amino acid insert was cloned into an expression vectors. Different GFPT1 
mutants were generated by site directed mutagenesis. Heterologous protein expression of the 
GFPT1 mutants p.Thr15Ala, p.Asp43Val and p.Asp348Tyr in HEK293 cells had only small effects 
on enzymatic activity and the mutations p.Arg111Cys and p.Arg43His had no effect at all (Figure 
19). Based on the structural model of the Escherichia coli ortholog for GFPT1 (GlmS) and the 
crystal structure of the isomerase domain of human GFPT1 [80], no functional consequences can 
be predicted for the GFPT1 missense mutations analysed in this study. Consistently, no gross 
changes in enzyme activity were observed for GFPT1 mutants by the glutamate dehydrogenase 
(GDH) assay (Figure 19).  
It is still conceivable that use of an alternative enzymatic assay might reveal activity changes of 
GFPT1 mutants. Three methods have been developed to measure the GFPT1 enzyme activity. In 
the present study, the glutamate dehydrogenase (GDH) method has been used. This method 
allows continuous determination of the GFPT1 activity with limited effort but also with less 
specificity. As the glutamate production is not always coupled to the amidotransferase activity of 
GFPT1, the GDH method has its limitations in screening inhibitors of the fructose-6-phosphate 
binding site of GFPT1 [162]. This method has been used since our laboratory was fully equipped 
with all required facilities.      
The most frequently used assay is the highly specific and relatively sensitive Elson-Morgan 
method [163, 164]. It is based on N-acetylation of the amino sugar phosphate, incubation in 
alkaline potassium tetraborate solution and condensation with p-dimethylaminobenzaldeyde. The 
third step leads to the formation of a purple product which has the absorption maximum at 595 
nm. The third method is the most sensitive one and based on a radiometric assay [165] which 
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allows the determination of picomolar amounts of GFPT1. However, this assay is very laborious 
and technically demanding.    
 
3 A 3’-UTR mutation creates a microRNA target site in the 
GFPT1 gene of LG-CMS patients 
 
3’-untranslated regions (UTRs) are involved in diverse regulatory roles at multiple levels. They 
play an important role in gene expression regulation by determination of mRNA 
stability/degradation, subcellular localization, nuclear export and translation efficiency [166-168]. 
The analysis of 3’-UTRs of some 17,700 human genes identified about 100 highly conserved 
motifs in human 3’-UTRs by comparison of several mammals. Many of them (about one-half) 
turned out to be microRNA target sites and the results suggested that at least 20 % of human 
genes are regulated by miRNAs [169]. Currently, mutations within proximal gene regulatory 
regions comprises only approximately 1.7 % of known mutations associated with human 
inherited disease [170]. However, this might be an underestimation as 3’-UTRs are less likely to 
be sequenced for mutations in research testing or routine diagnostic procedures especially if they 
are large.  
One of the identified GFPT1 mutations in four independent families from Spain (LGM5 and 12) 
and Germany (LGM9 and patient 4) was a 3’-UTR mutation c.*22C>A. In all four families, the 
mutation was compound heterozygous to missense or protein truncating mutations. The 
c.*22C>A variant lies 22 bp after the TGA translation termination codon in the 3’-UTR of the 
GFPT1 gene. Western blot analysis revealed that GFPT1 mutations generally lead to reduced 
GFPT1 protein levels in patient muscle and cultured muscle cells [65] and this was observed for 
patients of LGM5 and LGM9 with the c.*22C>A mutation as well (Figure 13). Nevertheless, the 
pathogenic mechanism of the c.*22C>A mutation which is located after the open reading frame 
(ORF) (Figure 20) of GFPT1 remained unclear. Transfection experiments in C2C12 cells linked the 
3’-UTR mutation directly to a reduced GFPT1 protein level in a controlled experiment (Figure 23 
A). Compared to wild-type, the expression level of the mutant construct was reduced to 36 % 
(Figure 23 B). Several expression regulation mechanisms have to be taken into account in order 
to further clarify the pathomechanism of the 3’-UTR mutation. 
One mechanism of expression regulation is based on miRNA binding to its target mRNA. These 
small non-coding RNAs participate in post-transcriptional regulation through imperfect sequence 
complementarity to the 3′-untranslated regions of the target mRNAs. The binding results in 
translational repression through the degradation of the mRNA or translational inhibition [171]. 
Encoded by nuclear DNA, primary miRNAs (pri-miRNAs) are processed to precursor miRNA (pre-
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miRNA) hairpins and transported to the cytoplasm where they are cleaved by Dicer, resulting in 
miRNA duplexes of about 21-23 nucleotides. Subsequently, the strands are selectively loaded into 
the RNA-induced silencing complex (RISC) [171, 172]. Strand selection correlates with the 
thermodynamic stability of each end of the duplex [173-175]. The more abundant and 
biologically active strand is called miRNA, whereas its less abundant partner and inactive strand is 
known as the star-form miRNA (miRNA*) [172, 176]. Since the star-form is rarely expressed, the 
functions of the miRNA* have not been taken into account [177]. However, recent studies 
revealed that some miRNA* species are relatively abundant in total RNA and that the star-form 
miRNAs may also have an important regulatory function [176-178]. In addition, miRNA/miRNA* 
ratios seems to vary dramatically among developmental stages [174, 179, 180]. 
In this study, the pathogenic effects of the c.*22C>A mutation in the 3’-UTR of the GFPT1 gene 
was investigated and the hypothesis that this mutation might interfere with microRNA-mediated 
gene regulation was confirmed.  
 
3.1 The GFPT1 3’-UTR mutation leads to the gain of a putative 
binding site for microRNAs 
 
Computer algorithms predicted that miR-600 and miR-206* would bind to the mutant GFPT1 
mRNA. The predicted microRNA binding site is present in the GFPT1 3’-UTR and alignments of 
the 3’-UTR of GFPT1 mRNA and the predicted microRNAs confirmed increased probability for 
miRNA binding to the mutant mRNA (Figure 24). The predicted miR-600 site in GFPT1 mutant 3’-
UTR is a 7mer-A1 seed match type (an exact match to positions 2-7 of the mature miRNA 
followed by an Adenine; Figure 24). Four types of seed-matched sites are known to be selectively 
conserved [181]: 6mer, 7mer-m8, 7mer-A1 and the 8mer site with the following hierarchy of site 
efficacy: 8mer > 7mer-m8 > 7mer-A1 > 6mer [182, 183]. Although there is no perfect miR-
206*:mutant GFPT1 mRNA seed matching (position 2-7 of the mature miRNA) there seems to be 
a compensatory base pairing site in the 3’ region of the miR-206* (Figure 24). Perfect miRNA 
seed matches are often necessary and sufficient for target regulation [184-187] and they are the 
basis of most of the genome wide predictions of miRNA binding sites [188-190]. However, recent 
studies presented 3’-supplementary, 3’-compensatory pairing and “centered sites” as new classes 
of microRNA target sites [182, 191]. The 5’ region of the microRNA, containing the seed region, 
is the most highly conserved region of the mature miRNA and it is therefore the most important 
site for target recognition [188, 192]. The next most highly conserved region spans from 
nucleotides 13 to 16. It is the region most important for 3’-supplementary and 3’-compensatory 
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pairing [182]. Centered sites lack both, perfect seed pairing and 3’-compensatory pairing, and 
instead have 11–12 contiguous Watson–Crick pairs to the center of the microRNA [191].   
 
3.1.1 Dual-luciferase reporter assays support the hypothesis that the 
GFPT1 3’-UTR mutation c.*22C>A leads to reduced GFPT1 protein 
amounts 
In order to test the interaction between the mutant GFPT1 transcript and the microRNAs directly, 
dual-luciferase reporter assays were performed. COS-7 cells were co-transfected with control 
miRNA, miR-600 or miR-206* mimics and reporter constructs containing wild-type or mutant 
GFPT1 3’-UTR sequences downstream of a luciferase reporter gene. In agreement with the 
predictions the mutant reporter constructs co-transfected with either miR-600 or miR-206* 
yielded significantly diminished reporter signals compared to the signal obtained by co-
transfection with the control miRNA (Figure 30 A and 33). Therefore, the results support a model 
in which the point mutation c.*22C>A in the GFPT1 3’-UTR creates a target site for two miRNAs, 
miR-600 and miR-206*, which influence GFPT1 expression.  
Up to now, there are only a few examples which link gene expression regulation through miRNAs 
and human diseases. A mutation in the 3’-UTR of the HDAC6 gene located in the seed region of 
hsa-mir-433 has been shown to abolish post-transcriptional regulation in a patient with X-linked 
chondrodysplasia [193]. In patients with Tourette syndrome, a variant in the 3′-UTR of the 
SLITRK1 gene was found to create a hsa-miR-189 binding site with higher affinity leading to 
repression of SLITRK1 expression [194]. Furthermore, miRNAs (miR-140 and miR-691) might be 
involved in the pathogenesis of hereditary spastic paraplegia (HSP) as they regulate expression of 
the HSP gene REEP1 [195, 196]. In the future, the identification of functional miRNA targets 
could greatly benefit from new assays based on crosslinking immunoprecipitation (HITS-CLIP). 
Recently, sequence analysis of RNAs isolated by HITS-CLIP has led to the identification of 
functional interaction sites [197]. 
 
3.2 Repression of translation results in reduced GFPT1 protein 
amounts in LG-CMS patients 
 
Quantification of GFPT1 mRNA levels in total RNA samples derived from myoblast and muscle 
samples of GFPT1 patients compound heterozygous for c.*22C>A, and control individuals (Figure 
21 and 22) indicates that the reduced amounts of GFPT1 protein levels in myoblast and muscle 
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lysates reported in the study (Figure 13) [65] resulted from repression of translation rather than 
altered mRNA stability. Compared to immunoblot results which revealed markedly reduced GFPT1 
protein level in GFPT1 patients (Figure 13), the effects on GFPT1 mRNA level are less distinct 
(Figure 21 and 22). Therefore, control of translation might be rather the pathogenic effect of the 
mutation than degradation of the target mRNA. It has been shown that destabilization of target 
mRNA by microRNAs account for most (>/=84 %) of the reduced protein expression. This study 
indicates that altered mRNA levels might reflect the impact of miRNAs on gene expression [198]. 
Reduced GFPT1 protein levels seem to result from repression of translation rather than 
degradation of the mRNA. Although most miRNAs act through destabilization of target mRNA, 
other miRNAs have been shown to affect translation. In a recent study about 16 % of the 
analysed miRNAs decrease translational efficiency of the target mRNAs [198]. Furthermore, it has 
to be taken into account that the GFPT1 patients (LGM 5 and 9) carry a 2nd GFPT1 mutation on 
the other allele (Table 15) and that the reduced GFPT1 protein amounts (Figure 13) [65] and the 
effects on the mRNA level in myoblast (Figure 21) und muscle lysates (Figure 22) reflect the 
impact of both mutations.   
 
3.3 c.*22C>A mutation allows for illegitimate binding of miRNA 
  
Several results confirm that the c.*22C>A mutation in the 3’-UTR is a causative mutation 
resulting in reduced protein expression. First of all, the mutation (LGM5 and LGM9) was 
associated with reduced amounts of GFPT1 in lysates of patients’ myoblast cells (Figure 13). 
Secondly, the mutation was found in four unrelated families (LGM5, 9, 12 and patient 4) and the 
c.*22C>A mutation was absent in a large number of control chromosomes [65]. Furthermore, 
experiments with expression constructs revealed a link between the 3’-UTR mutation and 
reduced GFPT1 protein amounts in C2C12 cells experimentally (Figure 23).  
Impaired glycosylation due to reduced amounts of functional GFPT1 protein (observed in two 
experimental approaches, Figure 13 and Figure 14) is presumably the pathogenic mechanism of 
GFPT1 mutations. Therefore, the co-transfection studies of the mutant GFPT1-3’-UTR construct 
with the miR-600 expression vector which revealed a functional effect on protein glycosylation 
(Figure 25) strongly suggest that the c.*22C>A mutation is a causative mutation. 
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3.4 Potential role of miRNA-206* and miR-600 in skeletal muscle 
 
MiR-206 has previously been shown to be strongly expressed in skeletal muscle and only rarely 
detectable in the heart [124-127, 199]. This skeletal muscle-specific expression of miR-206 sets it 
apart from the other myomiR (myo = muscle + miR = miRNA) family members [128]. So far, 
there is no information on the fate of its star-form miR-206* which I identified as a potential 
regulator of GFPT1 expression from the c.22*C>A allele.  
For the majority of miRNAs, only one strand (guide strand) of the double-stranded (ds) miRNA 
duplex is loaded into RISC while the other strand (star, *) is degraded rapidly [172, 200-202]. 
However, deep sequencing studies indicate that a large number of miRNA*s are loaded into the 
RISC and that the relative expression levels of the two strands vary widely among tissues [177, 
203-206]. It was proposed that the relative instability of the duplex termini determines which 
strand will be loaded. If both termini of the miRNA have almost the same stability, both strands 
might be selected [172]. An alternative model is proposed for miRNAs for which the two selected 
strands do not make a perfect miRNA duplex (with 2 nt overhangs) with similar stability on both 
termini. In this situation, the mature miRNA sequence, especially at the 5’ end is no longer fixed 
[207].    
To analyse the abundance of miR-206*, real-time qRT-PCR was performed of myoblast, myotube 
and muscle cDNA samples. Mature miR-206* is well detectable in muscle, myoblast and myotube 
samples obtained from GFPT1 patients and control individuals (Figure 26 A and 27 A). MiR-206 is 
known to be a critical regulator of skeletal muscle differentiation and regeneration [129, 131, 
208]. Recently, it has been shown that miR-206 is upregulated following muscle injury and it has 
been indicated that miR-206 slows progression of Duchenne muscular dystrophy [208]. The 
present thesis revealed that the miR-206* is also upregulated upon differentiation (Figure 27 A 
and B) and that both, the miR-206 and the star-form are more abundant in GFPT1 patients’ 
myoblasts than in controls (Figure 27 A and B). One may speculate that upregulation of miR-
206* is a similar generalized protective mechanism activated in diseased skeletal muscle. 
However, in the particular setting of the GFPT1 3’-UTR mutation allowing for improved binding of 
miR-206* this upregulation might initiate a vicious circle by further reducing the availability of 
functional GFPT1 in the cell instead of alleviating the disease process.  
The miR-600 expression has been reported in human colorectal cells [130], but not in muscle so 
far. The results of the present study showed the presence of hsa-miR600 in human muscle 
obtained from a GFPT1 patient heterozygous for c.*22C>A and c.1649C>T (Figure 26 B), 
suggesting a physiological role in the skeletal muscle. However, gel electrophoresis analysis of 
the PCR products revealed the presence of a second, non-specific fragment of approximately 110 
base pairs in human myoblasts and C2C12 cells (Figure 26 B).   
Marina Dusl  DISCUSSION 
 
107 
 
To date, several methods have been utilized for detection and quantification of miRNAs. They are 
largely based on cloning, northern blotting [209], or primer extension [210]. In this study, the 3’-
end of the miRNAs were first tailed with a common sequence by the E.coli Poly(A) Polymerase 
(PAP) [211] and then reverse transcribed by using a universal primer consisting of an oligo(dT) 
sequence with an universal primer-binding sequence at its 5’-region. A qPCR assay was used to 
detect and quantify the specific miRNAs by a miRNA-specific and a universal primer. The qPCR 
products were detected by using SYBR Green. False positive signal may arise from closely related 
miRNAs, precursors and genomic sequences. For instance, the target sequence is present in the 
primary transcript and the precursor, in addition to the mature miRNA [212]. Furthermore, SYBR 
Green binds to all dsDNA, including unspecific products such as primer-dimers [213]. In future, 
the presence of the non-specific hsa-miR600 amplification product has to be elucidated by 
optimization of the used detection method or by the use of another method (e.g. TaqMan 
probes).       
 
4 Expected consequences for human pathology diagnosis 
and therapy 
 
In general, a precise molecular classification of CMS is of paramount importance for the 
diagnosis, counseling and therapy of a patient. The identification of the molecular defect has 
direct impact on the clinical management of CMS patients [214]. In this thesis, it has been shown 
that mutations in a gene encoding an enzyme of a glycosylation pathway (GFPT1) underlie a 
form of congenital myasthenia with a limb-girdle pattern of weakness. In other fields of medicine, 
congenital disorders of glycosylation (CDGs) have been recognized as a rapidly expanding group 
of inherited disorders with a large spectrum of multisystemic phenotypes that are mostly 
combined with severe central neurological impairment [215]. 
However, glycosylation defects have not been considered to be implicated in disturbed signal 
transmission at the neuromuscular junction. Therefore, further research into the role of 
glycosylation in neuromuscular transmission may help in understanding synaptic processes.  
Thanks to its size and easy accessibility the NMJ is usually considered as a model synapse. Thus, 
understanding the correlation between inaccurate protein glycosylation and disturbed signal 
transmission at the neuromuscular junction might provide a helpful model for studying general 
aspects of glycosylation processes at central nervous system synapses. Although several findings 
suggest a postsynaptic origin of the neurotransmission defect in GFPT1 patients, it is important to 
clarify if it is indeed primarily postsynaptic or presynaptic, or a combination of pre- and 
postsynaptic abnormalities. This finding could be the basis for potential novel treatment options.    
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Traditionally, only 0.2 % of disease-associated mutations have been estimated to reside within 
3’-UTR [216] but recent findings suggest a higher rate. The data of the present thesis point 
toward the importance of extending molecular genetic analyses to UTRs, especially when only 
one heterozygous mutation is found in a recessive disease. In turn, interfering with miR-600 and 
miR-206* activity could provide a therapeutic option for patients with the c.*22C>A mutation. 
Sponge constructs and/or antagomirs against miR-600 and miR-206* might be tested for 
recovering GFPT1 protein levels in muscle.  
 
Administration of glucosamine might be an alternative treatment option for CMS patients with 
GFPT1 mutations. Glucosamine enters the hexosamine pathway downstream of the rate-limiting 
step catalyzed by the GFPT1 enzyme. It has been shown that when GFPT1 is bypassed by 
glucosamine it is able to elevate the O-GlcNAc levels in 3T3-L1 adipocytes [217]. Another 
strategy could be the treatment with saturated fatty acids. It has been shown that GFPT mRNA 
expression in primary myotubes can be upregulated by addition of the saturated fatty acids 
palmitate and stearate [218].  
 
Since the identification of the first CMS genes it has been recognized that biochemical studies of 
CMS-causing mutations may lead to a better understanding of the molecules involved in signal 
transmission at the NMJ and they may be useful to develop potential novel therapeutic 
approaches. This is especially true for the discovery of a defect in glycosylation as a previously 
unrecognized pathomechanism in a synaptic transmission disorder. 
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K Abbreviations  
 
aa    amino acid 
ab    antibody 
Acetyl-CoA  Acetyl-CoenzymeA 
ACh   Acetylcholine 
AChE/ACHE   Acetylcholinesterase/gene  
AChR   Acetylcholine receptor (nicotinic)  
αAChR   Acetylcholine receptor, alpha-subunit 
βAChR   Acetylcholine receptor, beta-subunit 
δAChR   Acetylcholine receptor, delta-subunit 
γAChR   Acetylcholine receptor, gamma-subunit 
εAChR   Acetylcholine receptor, epsilon-subunit 
BCA   bicinchonin acid 
BLAST   basic local alignment search tool 
bp    base pair/s 
BSA   bovine serum albumin 
°C   Grad Celsius  
cDNA    complementary DNA 
ChAT/CHAT  Cholin-Acetyltransferase/gene 
CHRNA1  gene coding for the alpha-subunit of the AChR 
CHRNB1  gene coding for the beta-subunit of the AChR 
CHRND   gene coding for the delta-subunit of the AChR 
CHRNE   gene coding for the epsilon-subunit of the AChR 
ColQ/COLQ  collagen tail/gene 
CMS   Congenital myasthenic syndrome 
CSK   cytoskeletal buffer  
d   day/s 
ddH2O    double-distilled water 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNTPs   mixture of all 4 deoxy ribonucleotides dATP, dTTP, dCTP, dGTP 
DTT   Dithiothreitol 
E.coli   Escherichia coli 
EDTA   ethylenediaminetetraacetic acid 
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ELISA   enzyme-linked immunosorbent assay 
HEK   Human embryonic kidney  
e.g.    exempli gratia, for example 
et al.    et alii, and others 
etc.    et cetera 
FCS   fetal calf serum 
g    gram 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GFP    green fluorescent protein 
GFPT1/GFPT1  glutamine-fructose-6- phosphate transaminase 1/gene (human) 
Gfpt1/Gfpt1  glutamine-fructose-6- phosphate transaminase 1/gene (mouse) 
GFPT1-L/GFAT1-L muscle-specific variant of glutamine-fructose-6- phosphate transaminase 1 
h    hour/hours 
hpf    hours post fertilization 
HRP   horseradish peroxidise 
hsa   Homo sapiens    
IF   Immunofluorescence 
l    liter 
kb   kilobase 
kDa    kilodaltons 
LB    Luria-Bertani 
LOD   Logarithm of odds 
min    minutes 
M    molar 
ml    millilitre 
mM    millimolar 
mRNA    messenger ribonucleic acid 
MuSK/MUSK  Muscle specific kinase/gene 
mut   mutant 
Myc   myelocytomatosis oncogene 
ng    nanogram 
nm    nanometer 
NTPs    nucleotide triphosphate mixture containing adenosine, guanidine, 
uridine and cytosine 
oan   Ornithorhynchus anatinus   
o.n.    over night 
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ORF    open reading frame 
PBS   phosphate buffered saline 
PCR    polymerase chain reaction 
PMSF   phenylmethylsulfonyl fluoride 
pol    RNA-polymerase II 
qRT-PCR  quantitative reverse transcription PCR 
Rapsyn/RAPSN  Receptor-associated protein of the synapse/gene 
RNA    ribonucleic acid 
rpm    revolutions per minute 
rt    room temperature 
RT    reverse transcription 
RT-PCR   reverse transcription polymerase chain reaction 
SCCMS   Slow-Channel CMS 
SCN4A   gene coding for the sodium channel 
sec    seconds 
SNP   Single nucleotide exchange polymorphism 
TE   Tris-EDTA 
Tris   Tris-(hydoxymethyl)-amminomethan  
UTR   untranslated region  
wt    wild-type 
WB   Western blot 
μg    microgram 
μl    microliter 
μM    micromolar 
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